(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
12 December 2002 (12.12.2002)

PCT

(10) International Publication Number
WO 02/098873 A1

(51) International Patent Classification[7]: C07D 409/04, 417/04, 401/04, 407/04, 403/04, 487/04, A61K 31/53, A61P 37/00, 29/00, 11/00, 11/06

(21) International Application Number: PCT/EP02/05540

(22) International Filing Date: 21 May 2002 (21.05.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0113343.8 1 June 2001 (01.06.2001) GB

(71) Applicant *(for all designated States except US)*: **BAYER AKTIENGESELLSCHAFT** [DE/DE]; 51368 Leverkusen (DE).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **ALONSO-ALIJA, Cristina** [ES/DE]; August-Macke-Weg 3, 42781 Haan (DE). **GIELEN, Heike** [DE/DE]; Am Kettnersbusch 3, 51379 Leverkusen (DE). **HENDRIX, Martin** [DE/DE]; Im Geroden 5, 51519 Odenthal (DE). **NIEWÖHNER, Ulrich** [DE/DE]; Gartenstr. 3, 42929 Wermelskirchen (DE). **SCHAUSS, Dagmar** [DE/DE]; Mittelstr. 36, 42697 Solingen (DE). **BISCHOFF, Hilmar** [DE/DE]; Am Rohm 78, 42113 Wuppertal (DE). **BURKHARDT, Nils** [DE/DE]; Hügelstr. 53, 40589 Düsseldorf (DE). **GEISS, Volker** [DE/DE]; Peddenkamp 58, 40883 Ratingen (DE). **SCHLEMMER, Karl-Heinz** [DE/DE]; Wildsteig 22 a, 42113 Wuppertal (DE).

(74) Common Representative: **BAYER AKTIENGESELLSCHAFT**; 51368 Leverkusen (DE).

(81) Designated States *(national)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.

(84) Designated States *(regional)*: ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declaration under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)*

Published:

— *with international search report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: 2-HETEROARYL-IMIDAZOTRIAZINONES AND THEIR USE IN THE TREATMENT OF INFLAMMATORY OR IMMUNE DISEASES



(I)

(57) Abstract: The invention relates to 2-Heteroaryl-imidazotriazinones, processes for their preparation and their use in medicaments, esp. for the treatment and/or prophylaxis of inflammatory processes and/or immune diseases. The present invention relates to compounds of the general formula (I) in which R^1 denotes 5- to 10- membered heteroaryl, which is optionally substituted by identical or different residues selected from the group consisting of halogen, (C_1-C_4)-alkyl, trifluoromthyl, cyano, nitro und trifluoromethoxy, denotes 3-to 10-membered carbocyclyl or carbon-bonded, 4- to 10-membered heterocyclyl, whereby carbocyclyl and heterocyclyl are optionally substituted by identical or different residues selected from the group consisting of (C_1-C_6)-aldyl, (C_1-C_6)-aldoxy, hydroxy, halogen, trifluoromethyl and oxo, or denotes (C_2-C_{10})-alkyl, which is optionally substituted by identical or different residues selected from the group the group consisting of (C_1-C_6)-alkoxy, hydroxy, halogen, 3-to 10-membered carbocyclyl and oxo.

WO 02/098873 A1

2-HETEROARYL-IMIDAZOTRIAZINONES AND THEIR USE IN THE TREATMENT OF INFLAMMATORY OR IMMUNE DISEASES

The invention relates to 2-Heteroaryl-imidazotriazinones, processes for their preparation and their use in medicaments, esp. for the treatment and/or prophylaxis of inflammatory processes and/or immune diseases.

Phosphodiesterases (PDEs) are a family of enzymes responsible for the metabolism of the intracellular second messengers cAMP (cyclic adenosine monophosphate) and cGMP (cyclic guanosine monophosphate). PDE 4, as a cAMP specific PDE, catalyses the conversion of cAMP to AMP and is the major if not sole isoform of the phosphodiesterase enzymes present in inflammatory and immune cell types. Inhibition of this enzyme leads to the accumulation of cAMP which, in these cells, leads to the inhibition of a range of pro-inflammatory functions. Uncontrolled production of inflammatory mediators can lead to acute and chronic inflammation, tissue damage, multi-organ failures and to death. Additionally, elevation of phagocyte cAMP leads to inhibition of oxygen radical production. This cell function is more sensitive than others such as aggregation or enzyme release.

It is now recognised that both asthma and COPD (Chronic obstructive pulmonary disease) are chronic inflammatory lung diseases. In the case of asthma the eosinophil is the predominant infiltrating cell. Subsequent release of superoxide radicals as well as damaging cationic proteins from these infiltrating cells are believed to play a role in the progression of the disease and development of airway hyperreactivity.

By contrast, in COPD the neutrophil is the predominant inflammatory cell type found in the lungs of sufferers. The action of mediators and proteases released in the environment of the lung is believed to result in the irreversible airway obstruction seen in COPD. In particular the action of proteases in degrading the lung matrix results in fewer alveoli and is likely to be the major cause of accelerated long term lung function decline seen in this disease.

Treatment with a PDE 4 inhibitor is expected to reduce the inflammatory cell burden in the lung in both of these diseases [M.S. Barnette, "PDE 4 inhibitors in asthma and chronic obstructive pulmonary disease", in: Progress in Drug Research, Birkhäuser Verlag, Basel, 1999, pp. 193-229; H.J. Dyke and J.G. Montana, "The therapeutic potential of PDE 4 inhibitors", Exp. Opin. Invest. Drugs 8, 1301-1325 (1999)].

WO 99/24433 and WO 99/67244 describe 2-phenyl-imidazotriazinones as synthetic intermediates for the synthesis of 2-(aminosulfonyl-phenyl)-imidazotriazinones as inhibitors of cGMP-metabolizing phosphodiesterases.

US-A-4,278,673 discloses 2-aryl-imidazotriazinones with cAMP phosphodiesterase inhibitory activity for the treatment of i.a. asthma.

The present invention relates to compounds of the general formula (I)



(I)

in which

R^1 denotes 5- to 10-membered heteroaryl, which is optionally substituted by identical or different residues selected from the group consisting of halogen, (C_1-C_4)-alkyl, trifluoromethyl, phenyl, cyano, nitro und trifluoromethoxy,

and

R^2 denotes 3- to 10-membered carbocyclyl or carbon-bonded, 4- to 10-membered heterocyclyl, whereby carbocyclyl and heterocyclyl are optionally substituted

by identical or different residues selected from the group consisting of (C_1-C_6)-alkyl, (C_1-C_6)-alkoxy, hydroxy, halogen, trifluoromethyl and oxo,
or
denotes (C_2-C_{10})-alkyl, which is optionally substituted by identical or different residues selected from the group consisting of (C_1-C_6)-alkoxy, hydroxy, halogen, 3- to 10-membered carbocyclyl and oxo.

Another embodiment of the invention relates to compounds of the general formula (I), in which

R^1 denotes furanyl, thiophenyl, thiazolyl, pyridyl, chinolyl or isochinolyl, which are optionally substituted by identical or different residues selected from the group consisting of halogen, (C_1-C_4)-alkyl, trifluoromethyl, cyano, nitro und trifluoromethoxy,

and R^2 has the meaning indicated above.

Another embodiment of the invention relates to compounds of the general formula (I), in which R^1 has the meaning indicated above, and

R^2 denotes (C_4-C_7)-cycloalkyl, which is optionally substituted up to two times by identical or different (C_1-C_5)-alkyl residues, or
denotes (C_3-C_8)-alkyl, which is optionally substituted by a (C_4-C_7)-cycloalkyl.

Preferred are compounds of the general formula (I), wherein R^2 denotes 4-*tert*-butyl-cyclohexyl.

Especially preferred are compounds of the general formula (I), wherein R^2 denotes *cis*-4-*tert*-butyl-cyclohexyl.

The compounds according to this invention can also be present in the form of their salts, hydrates and/or solvates.

In general, salts with organic or inorganic bases or acids may be mentioned here.

Physiologically acceptable salts are preferred in the context of the present invention.

Physiologically acceptable salts can also be salts of the compounds according to this invention with inorganic or organic acids. Preferred salts are those with inorganic acids such as, for example, hydrochloric acid, hydrobromic acid, phosphoric acid or sulphuric acid, or salts with organic carboxylic or sulphonic acids such as, for example, acetic acid, maleic acid, fumaric acid, malic acid, citric acid, tartaric acid, ethanesulphonic acid, benzenesulphonic acid, toluenesulphonic acid or naphthalenedisulphonic acid. Preferred pyridinium salts are salts in combination with halogen.

The compounds according to this invention can exist in stereoisomeric forms which either behave as image and mirror image (enantiomers), or which do not behave as image and mirror image (diastereomers). The invention relates both to the enantiomers and to the racemates, as well as the pure diastereomer and mixtures thereof. The racemates, like the diastereomers, can be separated into the stereoisomerically uniform constituents according to known methods.

Hydrates of the compounds of the invention are stoichiometric compositions of the compounds with water, such as for example hemi-, mono-, or dihydrates.

Solvates of the compounds of the invention or their salts are stoichiometric compositions of the compounds with solvents.

$(C_1\text{-}C_6)$-Alkoxy in general represents a straight chain or branched alkoxy residue with 1 to 6 carbon atoms. The following alkoxy residues are mentioned by way of example: methoxy, ethoxy, n-propoxy, isopropoxy, tert.butoxy, n-pentoxy and n-

hexoxy. Alkoxy residues with 1 to 4 carbon atoms are preferred. Alkoxy residues with 1 to 3 carbon atoms are especially preferred.

$(C_2$-$C_{10})$-Alkyl, $(C_1$-$C_8)$-alkyl, $(C_1$-$C_6)$-alkyl, and $(C_1$-$C_4)$-alkyl in general represent straight chain or branched alkyl residues with 2 to 10, 1 to 8, 1 to 6 or 1 to 4 carbon atoms, respectively. The alkyl residues can be saturated or partially unsaturated, i.e. contain one or more double and/or triple bonds. Saturated alkyl residues are preferred. The following alkyl residues are mentioned by way of example: methyl, ethyl, n-propyl, isopropyl, allyl, propargyl, tert.butyl, pentyl, hexyl, heptyl, octyl, nonyl, and decyl.

$(C_6$-$C_{10})$-Aryl in general represents an aromatic residue with 6 to 10 carbon atoms. Phenyl and naphthyl are preferred.

3- to 10-membered carbocyclyl in general represents a mono- or polycyclic, carbocyclic residue with 3 to 10 ring atoms. 3- to 8-membered carbocyclyl is preferred. Mono- and bicyclic carbocyclyl residues are preferred. Especially preferred are monocyclic carbocyclyl residues. The carbocyclyl residues can be saturated or partially unsaturated. Saturated carbocyclyl residues are preferred. Especially preferred are $(C_3$-$C_{10})$-cycloalkyl and $(C_4$-$C_7)$-cycloalkyl residues. The following carbocyclyl residues are mentioned by way of example: cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cycloheptyl, norborn-1-yl, norborn-2-yl, norborn-7-yl, norborn-2-en-7-yl, cyclooctyl, cubyl, cyclononyl, cyclodecyl, decalinyl, adamant-1-yl, adamant-2-yl.

$(C_3$-$C_{10})$-Cycloalkyl and $(C_4$-$C_7)$-cycloalkyl in general represent a cycloalkyl residue with 3 to 10 or 4 to 7 carbon atoms, respectively. The following cycloalkyl residues are mentioned by way of example: cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, or cyclodecyl.

Halogen in general represents fluoro, chloro, bromo and iodo. Fluoro, chloro, and bromo are preferred. Fluoro, and chloro are especially preferred.

5- to 10-membered heteroaryl in general represents a mono- or bicyclic, heteroaromatic residue with 5 to 10 ring atoms. Up to 4, preferably up to 2 ring atoms can be identical or different heteroatoms, preferably selected from N, O, and S. The following heteroaryl residues are mentioned by way of example: thienyl, furyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, oxazolyl, thiazolyl, isothiazolyl, pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, indolyl, quinolyl, isoquinolyl, quinazolyl, quinoxazolyl, benzothiazolyl, benzisothiazolyl, benzoxazolyl, isoxazolyl, benzimidazolyl, and oxazolinyl.

Carbon-bonded, 4- to 10-membered heterocyclyl in general represents a mono- or polycyclic, heterocyclic residue with 4 to 10 ring atoms, whereby the heterocycle is bound through a ring carbon ring atom. The heterocyclyl residue can contain up to 3, preferably 1, hetero ring atoms selected from nitrogen, oxygen, sulfur, -SO-, $-SO_2-$. Oxygen is preferred. Mono- and bicyclic heterocyclyl residues are preferred. Especially preferred are monocyclic heterocyclyl residues. The heterocyclyl residues can be saturated or partially unsaturated. Saturated heterocyclyl residues are preferred. The following heterocyclyl residues are mentioned by way of example: oxetan-3-yl, pyrrolidin-2-yl, pyrrolidin-3-yl, pyrrolinyl, tetrahydrofuranyl, tetrahydrothienyl, pyranyl, piperidinyl, thiopyranyl, morpholinyl, perhydroazepinyl.

Oxo in general represents a double-bonded oxygen atom.

Unless specified otherwise, when groups in compounds of the invention are optionally substituted, substitution by up to three identical or different residues is generally preferred.

The invention furthermore provides a process for preparing the compounds of the general formula (I) according to the invention, characterized in that

compounds of the general formula (II)



(II)

in which

R^2 is as defined above

and

L represents straight-chain or branched alkyl having up to 4 carbon atoms,

are condensed with compounds of the general formula (III)



(III)

in which

R^1 is as defined above,

preferably using ethanol as a solvent, to the compounds of the general formula (IV),



(IV)

in which R^1 and R^2 are as defined above,

which can optionally after isolation be reacted with a dehydrating agent, preferably phosphorus oxytrichloride, to yield the compounds of the general formula (I).

The compounds of the general formula (IV) can alternatively be prepared by

[A] condensation of compounds of the general formula (IIa),



(IIa)

in which

L is as defined above,

with compounds of the general formula (III) to compounds of the general formula (IVa),



(IVa)

in which

R^1 is as defined above,

preferably using ethanol as a solvent,

[B] followed by hydrolysis of the compounds of the general formula (IVa) to compounds of the general formula (V),



(V)

in which

R^1 is as defined above,

[C] and finally by condensation of the compounds of the general formula (V) with compounds of the general formula (VI),



(VI)

in which

R^2 is as defined above, and

T represents a leaving group, preferably chlorine.

The process according to the invention can be illustrated using the following scheme as an example:



Solvents which are suitable for the individual steps are the customary organic solvents which do not change under the reaction conditions. These preferably include ethers, such as diethyl ether, dioxane, tetrahydrofuran, glycol dimethyl ether, or hydrocarbons, such as benzene, toluene, xylene, hexane, cyclohexane or mineral oil fractions, or halogenated hydrocarbons, such as dichloromethane, trichloromethane, carbon tetrachloride, dichloroethane, trichloroethylene or chlorobenzene, or ethyl acetate, dimethylformamide, hexamethylphosphoric triamide, acetonitrile, acetone, dimethoxyethane or pyridine. It is also possible to use mixtures of the abovementioned solvents. Particular

preference is given to ethanol for the reaction II/IIa + III → IV/IVa and dichloroethane for the cyclisation IV → I .

The reaction temperature can generally be varied within a relatively wide range. In general, the reaction is carried out in a range of from -20°C to 200°C, preferably of from 0°C to 100°C.

The process steps according to the invention are generally carried out under atmospheric pressure. However, it is also possible to operate under superatmospheric pressure or under reduced pressure (for example, in a range of from 0.5 to 5 bar).

The compounds of the general formula (IVa) are preferably hydrolysed to compounds of the general formula (V) under acidic conditions as for example in refluxing 2N hydrochloric acid.

The compounds of the general formula (V) are condensed with the compounds of the general formula (VI) to compounds of the general formula (IV) in inert solvents, if appropriate in the presence of a base.

Suitable inert solvents are the customary organic solvents which do not change under the reaction conditions. These preferably include ethers, such as diethyl ether, dioxane, tetrahydrofuran, glycol dimethyl ether, or hydrocarbons, such as benzene, toluene, xylene, hexane, cyclohexane or mineral oil fractions, or halogenated hydrocarbons, such as dichloromethane, trichloromethane, carbon tetrachloride, dichloroethylene, trichloroethylene or chlorobenzene, or ethyl acetate, dimethylformamide, hexamethylphosphoric triamide, acetonitrile, acetone, dimethoxyethane or pyridine. It is also possible to use mixtures of the abovementioned solvents.

Suitable bases are generally alkali metal hydrides or alkali metal alkoxides, such as, for example, sodium hydride or potassium tert-butoxide, or cyclic amines, such as, for example, piperidine, pyridine, dimethylaminopyridine or (C_1-C_4)- alkylamines, such as,

for example, triethylamine. Preference is given to triethylamine, pyridine and/or dimethylaminopyridine.

The base is generally employed in an amount of from 1 mol to 4 mol, preferably from 1.2 mol to 3 mol, in each case based on 1 mol of the compound of the formula (V).

The reaction temperature can generally be varied within a relatively wide range. In general, the reaction is carried out in a range of from -20°C to 200°C, preferably of from 0°C to 100°C.

Some of the compounds of the general formula (II) are known, or they are novel, and they can then be prepared by

converting compounds of the general formula (VI)

$$R^2\text{-CO-T} \qquad \text{(VI)}$$

in which

R^2 is as defined above

and

T represents halogen, preferably chlorine,

initially by reaction with α-amino-butyric acid in inert solvents, if appropriate in the presence of a base and trimethylsilyl chloride, into the compounds of the general formula (VII),



(VII)

in which

R^2 is as defined above,

and finally reacting with the compound of the formula (VIII)



(VIII)

in which

L is as defined above,

in inert solvents, if appropriate in the presence of a base.

The compounds of the general formula (IIa) can be prepared analogously.

Suitable solvents for the individual steps of the process are the customary organic solvents which do not change under the reaction conditions. These preferably include ethers, such as diethyl ether, dioxane, tetrahydrofuran, glycol dimethyl ether, or hydrocarbons, such as benzene, toluene, xylene, hexane, cyclohexane or mineral oil fractions, or halogenated hydrocarbons, such as dichloromethane, trichloromethane, carbon tetrachloride, dichloroethylene, trichloroethylene or chlorobenzene, or ethyl acetate, dimethylformamide, hexamethylphosphoric triamide, acetonitrile, acetone, dimethoxyethane or pyridine. It is also possible to use mixtures of the abovementioned solvents. Particular preference is given to dichloromethane for the first step and to a mixture of tetrahydrofuran and pyridine for the second step.

Suitable bases are generally alkali metal hydrides or alkali metal alkoxides, such as, for example, sodium hydride or potassium tert-butoxide, or cyclic amines, such as, for example, piperidine, pyridine, dimethylaminopyridine or (C_1-C_4)-alkylamines, such as,

for example, triethylamine. Preference is given to triethylamine, pyridine and/or dimethylaminopyridine.

The base is generally employed in an amount of from 1 mol to 4 mol, preferably from 1.2 mol to 3 mol, in each case based on 1 mol of the compound of the formula (X).

The reaction temperature can generally be varied within a relatively wide range. In general, the reaction is carried out in a range of from -20°C to 200°C, preferably of from 0°C to 100°C.

The compounds of the general formulae (VI) and (VIII) are known per se, or they can be prepared by customary methods.

The compounds of the general formula (III) are known or can be prepared by

reacting compounds of the general formula (IX)

$$R^1\text{-}Y \qquad (IX)$$

in which

R^1 is as defined above, and

Y represents a cyano, carboxyl, methoxycarbonyl or ethoxycarbonyl group,

with ammonium chloride in toluene and in the presence of trimethylaluminium in hexane in a temperature range of from -20°C to room temperature, preferably at 0°C and atmospheric pressure, and reacting the resulting amidine, if appropriate in situ, with hydrazine hydrate.

The compounds of the general formula (IX) are known per se, or they can be prepared by customary methods.

The compounds of the general formula (I) inhibit the PDE 4 resident in the membranes of human neutrophils. One measured functional consequence of this inhibition was inhibition of superoxide anion production by stimulated human neutrophils.

The compounds of the general formula (I) can therefore be employed in medicaments for the treatment of inflammatory processes, esp. acute and chronic inflammatory processes, and/or immune diseases.

The compounds according to the invention are preferably suitable for the treatment and prevention of inflammatory processes, i.e. acute and chronic inflammatory processes, and/or immune diseases, such as emphysema, alveolitis, shock lung, all kinds of chronic obstructive pulmonary diseases (COPD), adult respiratory distress syndrome (ARDS), asthma, bronchitis, cystic fibrosis, eosinophilic granuloma, arteriosclerosis, arthrosis, inflammation of the gastro-intestinal tract, myocarditis, bone resorption diseases, reperfusion injury, Crohn's disease, ulcerative colitis, systemic lupus erythematosus, type I diabetes mellitus, psoriasis, anaphylactoid purpura nephritis, chronic glomerulonephritis, inflammatory bowel disease, atopic dermatitis, other benign and malignant proliferative skin diseases, allergic rhinitis, allergic conjunctivitis, vernal conjunctivitis, arterial restenosis, sepsis and septic shock, toxic shock syndrome, grafts vs. host reaction, allograft rejection, treatment of cytokine-mediated chronic tissue degeneration, rheumatoid arthritis, arthritis, rheumatoid spondylitis, osteoarthritis, coronary insufficiency, myalgias, multiple sclerosis, malaria, AIDS, cachexia, prevention of tumor growth and tissue invasion, leukemia, depression, memory impairment and acute stroke. The compounds according to the invention are additionally suitable for reducing the damage to infarct tissue after reoxygenation.

The compounds of formula (I) according to the invention can be used as active compound components for the production of medicaments. For this, they can be converted into the customary formulations such as tablets, coated tablets, aerosols, pills, granules, syrups, emulsions, suspensions and solutions in a known manner using

inert, non-toxic, pharmaceutically suitable excipients or solvents. Preferably, the compounds according to the invention are used here in an amount such that their concentration in the total mixture is approximately 0.5 to approximately 90% by weight, the concentration, inter alia, being dependent on the corresponding indication of the medicament.

The above mentioned formulations are produced, for example, by extending the active compounds with solvents and/or excipients having the above properties, where, if appropriate, additionally emulsifiers or dispersants and, in the case of water as the solvent, alternatively an organic solvent, have to be added.

Administration is carried out in a customary manner, preferably orally, transdermally or parenterally, for example perlingually, buccally, intravenously, nasally, rectally or inhalationally.

For human use, in the case of oral administration, it is recommendable to administer doses of from 0.001 to 50 mg/kg, preferably of 0.01 mg/kg - 20 mg/kg. In the case of parenteral administration, such as, for example, intravenously or via mucous membranes nasally, buccally or inhalationally, it is recommendable to use doses of 0.001 mg/kg - 0.5 mg/kg.

In spite of this, if appropriate, it may be necessary to depart from the amounts mentioned above, namely depending on the body weight or the type of administration route, on the individual response towards the medicament, the manner of its formulation and the time or interval at which administration takes place. Thus, in some cases it may be sufficient to manage with less than the above mentioned minimum amount, while in other cases the upper limit mentioned must be exceeded. In the case of the administration of relatively large amounts, it may be recommendable to divide these into several individual doses over the course of the day.

Test descriptions

1. Preparation of human PMN

Human PMN (polymorphonuclear neutrophil leucocytes) are readily purified from peripheral blood. Phosphodiesterase in these cells is predominantly located in the membrane fraction. Inhibitory potency of compounds against this preparation correlate well with the anti-inflammatory activity as measured by inhibiton of superoxide production.

Blood was taken from healthy subjects by venous puncture and neutrophils were purified by dextran sedimentation and density gradient centrifugation on Ficoll Histopaque and resuspended in the buffered medium.

2. Assay of human PMN phosphodiesterase

This was performed as a particulate fraction from human PMN essentially as described by Souness and Scott [Biochem. J. 291, 389-395 (1993)]. Particulate fractions were treated with sodium vanadate / glutathione as described by the authors to express the discrete stereospecific site on the phosphodiesterase enzyme. The prototypical PDE 4 inhibitor, rolipram, had an IC_{50} value in the range 450 nM-1500 nM, thus defining this preparation as the so-called "low affinity" [L] form. The preparation examples had IC_{50} values within the range of 0.1 nM - 10,000 nM.

3. Inhibition of FMLP-stimulated production of superoxide radical anions

Neutrophils (2.5×10^5 ml^{-1}) were mixed with cytochrome C (1.2 mg/ml) in the wells of a microtitre plate. Compounds according to the invention were added in dimethyl sulphoxide (DMSO). Compound concentration ranged from 2.5 nM to 10 µM, the DMSO concentration was 0.1% v/v in all wells. After addition of

cytochalasin b (5 µg x ml^{-1}) the plate was incubated for 5 min at 37°C. Neutrophils were then stimulated by addition of 4 x 10^{-8} M FMLP (N-Formyl-Met-Leu-Phe) and superoxide generation measured as superoxide dismutase inhibitable reduction of cytochrome C by monitoring the OD_{550} in a Thermomax microtitre plate spectrophotometer. Initial rates were calculated using a Softmax kinetic calculation programme. Blank wells contained 200 units of superoxide dismutase.

The inhibition of superoxide production was calculated as follows:

$$\frac{[1-(Rx - Rb)]}{(Ro - Rb)} \times 100$$

Rx = Rate of the well containing the compound according to the invention

Ro = Rate in the control well

Rb = Rate in the superoxide dismutase containing blank well

4. Assay of binding to the rolipram binding site (PDE 4 high affinity site; "H-PDE 4 form") in rat brain membranes

The activity of compounds on the PDE 4 high affinity site ("H-PDE 4 form") is readily measured by determining their potency for displacement of [^{3}H]-rolipram from its binding site in rat brain membranes. Activity at this site is believed to be a measure of side effect potential (e.g. stimulation of stomach acid secretion, nausea and emesis).

The rolipram binding site assay was performed essentially as described by Schneider et al. [Eur. J. Pharmacol. 127, 105-115 (1986)].

5. Lipopolysaccharide (LPS) - induced neutrophil influx into rat lung

Intranasal administration of LPS to rats causes a marked influx of neutrophils into the lungs measurable by histological or biochemical (myeloperoxidase content of the cell pellet) analysis of the bronchoalveolar lavage fluid 24 h later. Rats were treated with test compound or vehicle administered by the oral route 1 h prior to and 6 h after administration of intranasal LPS. 24 hours later animals were euthanatized and their lungs lavaged with PBS (phosphate buffered saline). Neutrophil and total cell numbers were analysed.

6. Emetic potential in the marmoset

Vehicle or test compound was administered by the oral route to conscious marmosets. Animals were observed for emetic episodes or abnormal behaviour for 1 h post dosing. In some experiments, if no adverse response was seen, a separate group of animals was tested at ½ log dose higher until emesis or abnormal behaviour was observed. The highest dose at which no abnormal behavior or emetic episodes occurred was recorded as the NOEL.

Materials and Methods

LC-MS method A

LC-parameters: solution A acetonitrile
solution B 0.3 g 30% HCl/l water
column oven 50°C;
column Symmetry C18 2.1 x 150 mm

gradient :

time [min]	%A	%B	flow [ml/min]
0	10	90	0.9
3	90	10	1.2
6	90	10	1.2

LC-MS method B

LC-parameters: solution A acetonitrile/0.1% formic acid
solution B water/0.1% formic acid
column oven 40°C;
column Symmetry C18 2.1 x 50 mm

gradient :

time [min]	%A	%B	flow [ml/min]
0	10	90	0.5
4	90	10	0.5
6	90	10	0.5
6.1	10	90	1.0
7.5	10	90	0.5

GC-MS method A

Column: HP-5 30m x 320µm x 0.25µm
Carrier Gas: Helium
Mode: constant flow, initial flow: 1.5 ml/min
Oven ramp: initial temp: 60°C
initial time: 1 min
rate: 14°C/min up to 300°C, then 300°C 2 min

Unless specified otherwise, the following chromatographic conditions were applied: chromatography was performed on silica gel Si 60; for flash chromatography, the usual conditions were followed as described in Still, *J. Org. Chem.* 43, 2923 (1978); mixtures of dichloromethane and methanol or cyclohexane and ethylacetate were used as eluants. Unless specified otherwise, reactions were executed under an argon atmosphere and under anhydrous conditions.

Abbreviations

HPLC	=	high performance liquid chromatography
MS	=	mass spectroscopy
NMR	=	nuclear magnetic resonance spectroscopy
LC-MS	=	liquid chromatography combined with mass spectroscopy
GC-MS	=	gas chromatography combined with mass spectroscopy
MeOH	=	methanol
DMSO	=	dimethylsulfoxide

Starting Materials

Example 1A

2-(Acetylamino)butanoic acid



163 g (1.58 mol) 2-Aminobutanoic acid are dissolved in acetic acid, and 242 g (2.37 mol) acetic anhydride are added dropwise. The mixture is stirred for 2 h at 100°C until completion of reaction, then the solution evaporated to dryness *in vacuo*. The solid residue is suspended in ethyl acetate, filtered and washed with diethyl ether.

Yield: 220 g (96%)

^{1}H-NMR (Methanol-d_4): δ = 0,97 (t, 3 H), 1,65-1,93 (m, 2 H), 1,99 (s, 3 H), 4,29 (q, 1 H) ppm.

Example 2A

Ethyl 3-(acetylamino)-2-oxopentanoate



9.2 g (63.4 mmol) 2-(Acetylamino)butanoic acid are suspended in 120 ml tetrahydrofurane and heated to reflux together with 15.0 g (190 mmol) pyridine and a bit of *N,N*-dimethylaminopyridine. While heating at reflux, 17.3 g (127 mmol) ethyl chloro(oxo)acetate are added dropwise. The reaction mixture is heated at reflux until

no more evolution of gas can be observed. After cooling down to room temperature, the reaction mixture is added to ice water and the organic phase extracted with ethyl acetate. The dried organic phase is evaporated to dryness *in vacuo*, dissolved in ethanol and the solution directly used for the next reaction.

Example 3A

2-[(Cyclopentylcarbonyl)amino]butanoic acid



35 g (339 mmol) 2-aminobutanoic acid and 75,6 g (747 mmol) triethylamine are suspended in 300 ml of dichloromethane and stirred at 0°C. 81 g(747 mmol) chlorotrimethylsilane are added dropwise, then the mixture is stirred for 1hour at room temperature and 1hour at 40°C. After cooling down at -10°C, 45 g (339 mmol) cyclopentanecarbonyl chloride are added slowly. The reaction mixture is stirred for 2 hours at -10°C and then 1 hour at room temperature. At 0°C, 50 ml of water are added. The mixture is diluted with water and dichloromethane, filtered and the solid product washed with water/dichloromethane 9/1, toluene and diethylether.

Yield: 52.4 g (77%)

^{1}H-NMR (DMSO-d_6, 300 MHz): δ = 0,9 (t, 3H), 1,6 (m, 10H), 2,6 (m, 1H), 4,1 (m, 2H), 7,9 (d, 1H), 12,4 (s, 1H) ppm.

Example 4A

Ethyl 3-[(cyclopentylcarbonyl)amino]-2-oxopentanoate



1,6 g (8 mmol) 2-[(Cyclopentylcarbonyl)amino]butanoic acid are suspended in 30 ml tetrahydrofurane and heated to reflux together with 1,91 g (24 mmol) pyridine and a bit of *N,N*-dimethylaminopyridine. While heating at reflux, 2,19 g (16 mmol) ethyl chloro(oxo)acetate are added dropwise. The reaction mixture is heated at reflux until no more evolution of gas can be observed.. After cooling down to room temperature, the reaction mixture is added to ice water and the organic phase extracted with ethyl acetate. The dried organic phase is evaporated to dryness *in vacuo*, dissolved in ethanol and the solution directly used for the next reaction.

Example 5A

3-Thiophenecarboximidamide hydrochloride



x HCl

5,91 g (91,6 mmol, 2 equiv.) ammonium chloride are suspended in 40 ml of dry toluene under an argon atmosphere, and the mixture is cooled to 0°C. 45,8 ml (91,6 mmol, 2 equiv.) of a 2M solution of trimethylaluminium in hexane are added dropwise, and the reaction mixture is stirred at room temperature until no more evolution of gas is observed. After addition of 5,0 g (45,8 mmol) thiophene-3-carbonitrile, the mixture is stirred at 80°C bath temperature over night. It is then cooled down to 0°C and 50 ml of methanol are added with consequent stirring of 1 hour at room temperature. After filtration, the solid is washed with methanol for several times, the solution is evaporated to dryness in vacuo and the residue washed with methanol.

Yield: 6.7 g (90%)

^{1}H-NMR (DMSO-d_6, 200 MHz): δ = 7,7 (m, 1H), 7,8 (m, 1H), 8,7 (m, 1H), 9,0 (br.s, 2H), 9,4 (br.s, 2H) ppm.

Example 6A

2-Quinolinecarboximidamide hydrochloride



In analogy to the procedure for Example 5A, 10,0 g (64,9 mmol) 2-quinoline-carbonitrile and proportionate amounts of the other reagents are used.

Yield: 9.2 g (68%)

^{1}H-NMR (200 MHz, DMSO): δ = 7,83 (t, 1 H), 7,97 (t, 1 H), 8,19 (t, 2 H), 8,37 (d, 1 H), 8,77 (d, 1 H) ppm.

Example 7A

N-{1-[5-Oxo-3-(3-thienyl)-4,5-dihydro-1,2,4-triazin-6-yl]propyl}acetamide



6,5 g (8,6 mmol, 1 equiv.) (40 mmol) of Example 5A are suspended in 150 ml of ethanol and 6,92 g (48 mmol, 1,2 equiv.) hydrazine hydrate are added. After stirring at room temperature for 1 hour, 11,95 g (60 mmol, 1,5 equiv) of the compound of

Example 2A, dissolved in 30 ml of ethanol, are added. The reaction mixture is stirred at 80°C (bath temperature) for 4 hours and then at room temperature over night. The mixture is evaporated to dryness *in vacuo* and the product is purified by chromatography (flash or column chromatography or preparative HPLC).

Yield: 4.9 g (44%)

^{1}H-NMR (DMSO-d_6, 300 MHz): δ = 0,9 (t, 3H), 1,6 (m, 1H), 1,8 (m, 1H), 1,9 (s, 3H), 4,9 (m, 1H), 7,7 (m, 2H), 8,1 (m, 1H), 8,5 (m, 1H), 14,0 (br. s, 1H) ppm.

Example 8A

N-{1-[5-Oxo-3-(2-phenyl-1,3-thiazol-4-yl)-4,5-dihydro-1,2,4-triazin-6-yl]propyl}-acetamide



In analogy to the procedure for Example 7A, 1,0 g (4,2 mmol) 2-phenyl-1,3-thiazole-4-carboximidamide hydrochloride and proportionate amounts of the other reagents are used.

Yield: 655 mg (44%)

^{1}H-NMR (DMSO-d_6, 200 MHz): δ = 0,9 (t, 3H), 1,6 (m, 1H), 1,8 (m, 1H), 1,9 (s, 3H), 4,9 (m, 1H), 7,6 (m, 3H), 8,2 (m, 2H), 8,7 (s, 1H), 14,2 (br. s, 1H) ppm.

Example 9A

N-{1-[5-Oxo-3-(2-quinolinyl)-4,5-dihydro-1,2,4-triazin-6-yl]propyl}acetamide



In analogy to the procedure for Example 7A, 5,0 g (24,1 mmol) 2-quinolinecarboximidamide hydrochloride and proportionate amounts of the other reagents are used.

Yield: 6.0 g (54%)

LC/MS (method A): retention time 2.05 min., *m/z* 324 $[M+H]^+$

Example 10A

N-{1-[5-Oxo-3-(2-thienyl)-4,5-dihydro-1,2,4-triazin-6-yl]propyl}acetamide



In analogy to the procedure for Example 7A, 2,0 g (12,3 mmol) 2-thiophenecarboximidamide hydrochloride and proportionate amounts of the other reagents are used.

Yield: 0.6 g (15%)

^{1}H-NMR (DMSO-d_6, 200 MHz): δ = 0,9 (t, 3H), 1,6 (m, 1H), 1,8 (m, 1H), 1,9 (s, 3H), 4,9 (m, 1H), 7,3 (m, 1H), 8,0- 8,2 (m, 3H), 14,2 (br. s, 1H) ppm.

Example 11A

6-(1-Aminopropyl)-3-(3-thienyl)-1,2,4-triazin-5(4H)-one



4,9 g (17,6 mmol) Example 7A are heated to reflux in 50 ml 2 N hydrochloric acid for 3 hours. After cooling down to room teperature, the mixture is neutralized with 10% NaOH and, and, after addition of ethanol, evaporated to dryness *in vacuo*. The residue is treated with methanol and the filtrate separated from th salts. The filtrate is evaporated to dryness in vacuo and the crude product is directly used for the next step or the product is purified by chromatography (flash or column chromatography or preparative HPLC).

crude product:

LC/MS (B): MS (ES+): 237 ($M+H^+$), retention time 0.38 min

Example 12A

6-(1-Aminopropyl)-3-(2-phenyl-1,3-thiazol-4-yl)-1,2,4-triazin-5(4H)-one



In analogy to the procedure for Example 11A, 631 mg (1,8 mmol) of Example 8A and proportionate amounts of the other reagents are used.

Yield: 373 mg (67%)

^{1}H-NMR (DMSO-d_6, 200 MHz): δ = 1,2 (t, 3H), 1,7 (m, 1H), 1,9 (m, 1H), 3,9 (d/d, 1H), 4,9 (br.s, 2H), 7,5 (m, 3H), 8,0 (m, 2H), 8,2 (s, 1H) ppm.

Example 13A

6-(1-Aminopropyl)-3-(2-quinolinyl)-1,2,4-triazin-5(4H)-one



In analogy to the procedure for Example 11A, 6,0 g (18,6 mmol) N-{1-[5-oxo-3-(2-quinolinyl)-4,5-dihydro-1,2,4-triazin-6-yl]propyl}acetamide and proportionate amounts of the other reagents are used.

Yield: 3.1 g (42%)

MS (ESI+): 282 $[M+H]^+$

Example 14A

6-(1-Aminopropyl)-3-(2-thienyl)-1,2,4-triazin-5(4H)-one



In analogy to the procedure for Example 11A, 9,40 g (33,8 mmol) of Example 10A and proportionate amounts of the other reagents are used.

Yield: 5.07 g (63%)

^{1}H-NMR (DMSO-d_6, 200 MHz): δ = 0,9 (t, 3H), 1,9 (m, 2H), 4,2 (bs, 1H), 4,3 (m, 1H), 7,1 (dd, 1H), 7,7 (m, 1H), 7,8 (m, 1H), 8,3 (br. s, 2H) ppm.

Example 15A

N-{1-[5-Oxo-3-(2-phenyl-1,3-thiazol-4-yl)-4,5-dihydro-1,2,4-triazin-6-yl]propyl}-cyclopentanecarboxamide



170 mg (0,54 mmol, 1 equiv.) of Example 12A are suspended in 10 ml dichloromethane, 0,15 ml (1,08 mmol, 2 equiv.) triethylamine and 0,066 ml (0,54 mmol, 1 equiv.) cyclopentanecarbonyl chloride are added. The reaction mixture is stirred at room temperature until completion of reaction (1-2 hours). The reaction mixture is added to the same volume of 1N hydrochloric acid, the organic phase is washed with 1N hydrochloric acid and brine, dried over sodium sulfate and evaporated to dryness. The product is used without further purification or purified by chromatography (flash or column chromatography or preparative HPLC).

Yield: 182 mg (82%)

^{1}H-NMR (DMSO-d_6, 200 MHz): δ = 1,2 (t, 3H), 1,6-1,9 (m, 10H), 2,6 (m, 1H), 4,9 (m, 1H), 7,6 (m, 3H), 8,0 (d, 1H), 8,2 (m, 2H), 8,7 (s, 1H), 14,2 (br. s, 1H) ppm.

Example 16A

N-{1-[5-Oxo-3-(2-phenyl-1,3-thiazol-4-yl)-4,5-dihydro-1,2,4-triazin-6-yl]propyl}-cyclobutanecarboxamide



In analogy to the procedure for Example 15A, 188 mg (0,6 mmol) of Example 12A, 0,068 ml (0,6 mmol) cyclobutanecarbonyl chloride and proportionate amounts of the other reagents are used.

Yield: 218 mg (92%)

^{1}H-NMR (DMSO-d_6, 200 MHz): δ = 1,2 (t, 3H), 1,6-2,1 (m, 8H), 3,1 (m, 1H), 4,9 (m, 1H), 7,6 (m, 3H), 7,9 (d, 1H), 8,2 (m, 2H), 8,7 (s, 1H), 14,2 (br. S(1H) ppm.

Example 17A

N-{1-[5-Oxo-3-(3-thienyl)-4,5-dihydro-1,2,4-triazin-6-yl]propyl}cyclopentanecarboxamide



In analogy to the procedure for Example 15A, 400 mg (1,69 mmol) of Example 11A, 0,206 ml (1,69 mmol) cyclopentanecarbonyl chloride and proportionate amounts of the other reagents are used.

LC/MS (B): MS (ES+): 333 ($M+H^+$), retention time 3.05 min.

Example 18A

N-{1-[5-Oxo-3-(3-thienyl)-4,5-dihydro-1,2,4-triazin-6-yl]propyl}cyclobutanecarboxamide



In analogy to the procedure for Example 15A, 400 mg (1,69 mmol) of Example 11A, 0,193 ml (1,69 mmol) cyclobutanecarbonyl chloride and proportionate amounts of the other reagents are used.

LC/MS (B): MS (ES+): 319 ($M+H^+$), retention time 2.82 min.

Example 19A

4-tert-Butyl-N-{1-[5-oxo-3-(3-thienyl)-4,5-dihydro-1,2,4-triazin-6-yl]propyl}cyclohexanecarboxamide



In analogy to the procedure for Example 15A, 400 mg (1,69 mmol) of Example 11A, 343 mg (1,69 mmol) 4-tert-butylcyclohexanecarbonyl chloride and proportionate amounts of the other reagents are used.

LC/MS (B): MS (ES+): 403 ($M+H^+$), retention time 4.16 min.

Example 20A

N-{1-[5-Oxo-3-(2-quinolinyl)-4,5-dihydro-1,2,4-triazin-6-yl]propyl}cyclopentane-carboxamide



In analogy to the procedure for Example 15A, 500 mg (1,78 mmol) 6-(1-amino-propyl)-3-(2-quinolinyl)-1,2,4-triazin-5(4H)-one, 350 mg (2,67 mmol) cyclopentane-carbonyl chloride and proportionate amounts of the other reagents are used. The crude product is used in the next step without further purification.

Yield: 275 mg (41%) crude product.

Example 21A

N-{1-[5-Oxo-3-(4-pyridinyl)-4,5-dihydro-1,2,4-triazin-6-yl]propyl}cyclopentane-carboxamide



560 mg (3,56 mmol, 1 equiv.) 4-pyridinecarboximidamide hydrochloride are suspended in 10 ml of ethanol and 220 mg (4,27 mmol, 1,2 equiv.) hydrazine hydrate are added. After stirring at room temperature for 1 hour, 1,0 g (3,92 mmol, 1,1 equiv) of the compound of Example 4A, dissolved in 10 ml of ethanol, are added. The reaction mixture is stirred at 70°C (bath temperature) for 4 hours. The mixture is evaporated to dryness *in vacuo* and the product is purified by chromatography (flash or column chromatography or preparative HPLC).

Yield: 400 mg (34%)

^{1}H-NMR (DMSO-d_6, 200 MHz): δ = 0,9 (t, 3H), 1,4-1,9 (m, 10H), 2,7 (m, 1H), 4,9 (m, 1H), 8,0 (m, 3H), 8,8 (d, 2H), 14,3 (br. s, 1H) ppm.

Example 22A

N-{1-[3-(4,6-Dimethyl-2-pyridinyl)-5-oxo-4,5-dihydro-1,2,4-triazin-6-yl]propyl}-cyclopentanecarboxamide



In analogy to the procedure for Example 21A, 1,28 g (6,9 mmol) 4,6-dimethyl-2-pyridinecarboximidamide hydrochloride and proportionate amounts of the other reagents are used.

Yield: 2.25 g (crude)

LC/MS (A): MS (ESI): 356 ($M+H^+$), retention time 3.48 min.

Example 23A

N-{1-[5-Oxo-3-(3-pyridinyl)-4,5-dihydro-1,2,4-triazin-6-yl]propyl}cyclopentane-carboxamide



In analogy to the procedure for Example 21A, 1,28 g (6,9 mmol) 3-pyridinecarboximidamide hydrochloride hydrochloride and proportionate amounts of the other reagents are used.

Yield: 1.4 g (32%)

^{1}H-NMR (DMSO-d_6, 200 MHz): δ = 0,9 (t, 3H), 1,4-1,9 (m, 10H), 2,7 (m, 1H), 4,9 (m, 1H), 7,6 (m, 1H), 8,0 (d, 1H), 8,4 (m, 1H), 8,8 (m, 1H), 9,2 (m, 1H), 14,2 (br. s, 1H) ppm.

Example 24A

N-{1-[5-Oxo-3-(2-thienyl)-4,5-dihydro-1,2,4-triazin-6-yl]propyl}cyclopentanecarboxamide



In analogy to the procedure for Example 21A, 6,0 g (36,9 mmol) 2-thiophenecarboximidamide hydrochloride and proportionate amounts of the other reagents are used.

Yield: 0.5 g (4%)

^{1}H-NMR (DMSO-d_6, 200 MHz): δ = 0,9 (t, 3H), 1,4-1,9 (m, 10H), 2,7 (m, 1H), 4,9 (m, 1H), 7,3 (m, 1H), 8,0 (m, 2H), 8,1 (m, 1H), 14,2 (br. s, 1H) ppm.

Example 25A

N-{1-[5-Oxo-3-(2-pyridinyl)-4,5-dihydro-1,2,4-triazin-6-yl]propyl}cyclopentane-carboxamide



In analogy to the procedure for Example 21A, 2,8 g (17,8 mmol) 2-pyridinecarb-oximidamide hydrochloride and proportionate amounts of the other reagents are used.

Yield: 0.98 g (17%)

LC/MS (A): MS (ESI): 328 ($M+H^+$), retention time 3.02 min

Example 26A

N-{1-[5-Oxo-3-(2-furanyl)-4,5-dihydro-1,2,4-triazin-6-yl]propyl}cyclopentanecarb-oxamide



In analogy to the procedure for Example 21A, 1,3 g (8,9 mmol) 2-furancar-boximidamide hydrochloride hydrochloride and proportionate amounts of the other reagents are used.

Yield: 380 mg (13%)

^{1}H-NMR (DMSO-d_6, 200 MHz): δ = 0,9 (t, 3H), 1,4-1,9 (m, 10H), 2,7 (m, 1H), 4,9 (m, 1H), 6,8 (m, 1H), 7,4 (d, 1H), 8,0 (m, 1H), 8,1 (m, 1H), 14,1 (br. s, 1H) ppm.

Example 27A

cis-4-tert-Butyl-N-{1-[5-oxo-3-(2-thienyl)-4,5-dihydro-1,2,4-triazin-6-yl]propyl}-cyclohexanecarboxamide



In analogy to the procedure for Example 15A, 1,00 g (4,23 mmol) of Example 14A, 0,94 g (4,65 mmol) cis-4-tert-butylcyclohexanecarbonyl chloride and proportionate amounts of the other reagents are used.

Yield: 1.6 g (94%)

LC/MS (A): MS (ESI): 403 ($M+H^+$), retention time 4.25 min

Example 28A

N-{1-[5-Oxo-3-(2-thienyl)-4,5-dihydro-1,2,4-triazin-6-yl]propyl}cyclobutanecarboxamide



In analogy to the procedure for Example 15A, 103 mg (0,434 mmol) of Example 14A, 57 mg (0,478 mmol) cyclobutanecarbonyl chloride and proportionate amounts of the other reagents are used.

Yield: 140 mg (100%)

Example 29A

4-tert-Butyl-N-{1-[5-oxo-3-(2-thienyl)-4,5-dihydro-1,2,4-triazin-6-yl]propyl}cyclohexanecarboxamide



In analogy to the procedure for Example 15A, 350 mg (1,48 mmol) of Example 14A, 330 mg (1,63 mmol) 4-tert-butylcyclohexanecarbonyl chloride and proportionate amounts of the other reagents are used. A mixture of isomers is obtained.

Yield: 0.58 g (97%)

LC/MS (A): MS (ESI): 403 ($M+H^+$), retention time 4.25 min

Example 30A

3-Methyl-N-{1-[5-oxo-3-(2-thienyl)-4,5-dihydro-1,2,4-triazin-6-yl]propyl}butanamide



In analogy to the procedure for Example 15A, 85 mg (0,36 mmol) of Example 14A, 48 mg (0,40 mmol) 3-methylbutanoyl chloride and proportionate amounts of the other reagents are used.

Yield: 115 mg (crude)

LC/MS (A): MS (ESI): 321 ($M+H^+$), retention time 2.91 min

Example 31A

5-Chloro-2-thiophenecarboximidamide hydrochloride



In analogy to the procedure for Example 5A, 12,5 g (66 mmol) ethyl 5-chloro-2-thiophenecarboxylate and proportionate amounts of the other reagents are used.

Yield: 9.3 g (72%)

Example 32A

1-Isoquinolinecarboximidamide hydrochloride



In analogy to the procedure for Example 5A, 10,0 g (64,9 mmol) 2-quinoline-carbonitrile and proportionate amounts of the other reagents are used.

Yield: 3.8 g (88%)

^{1}H-NMR (400 MHz, CD_3OD): δ = 7,75 (t, 1 H), 7,81 (t, 1 H), 7,97-8,03 (m, 2 H), 8,11 (d, 1 H), 8,53 (d, 1 H) ppm.

Example 33A

3-Bromo-2-thiophenecarboximidamide hydrochloride



In analogy to the procedure for Example 5A, 15,0 g (79,8 mmol) 3-bromo-2-thiophenecarbonitrile and proportionate amounts of the other reagents are used.

Yield: 6.8 g (35%)

Example 34A

1,5-Dimethyl-1H-pyrrole-2-carboximidamide hydrochloride



In analogy to the procedure for Example 5A, 5.0 g (41.6 mmol) 1,5-dimethyl-1H-pyrrole-2-carbonitrile and proportionate amounts of the other reagents are used.

Yield: 5.85 g (81%)

^{1}H-NMR (200 MHz, DMSO): δ = 2.3 (s, 3H), 3.6 (s, 3H), 6.1 (m, 1H), 6.7 (m, 1H), 8.7 (br.m, 3H) ppm.

Example 35A

3-Chloro-2-pyridinecarboximidamide hydrochloride



In analogy to the procedure for Example 5A, 7.8 g (56.3 mmol) 3-chloro-2-pyridinecarbonitrile and proportionate amounts of the other reagents are used.

Yield: 9.7 g (90%)

^{1}H-NMR (300 MHz, DMSO): δ = 7.7 (d/d, 1H), 8.2 (d/d, 1H), 8.6 (br.m, 4H, 8.7 (d/d, 1H) ppm.

Example 36A

1H-Pyrrole-2-carboximidamide hydrochloride



In analogy to the procedure for Example 5A, 4.9 g (53.2 mmol) 1H-pyrrole-2-carbonitrile and proportionate amounts of the other reagents are used.

Yield: 2.2 g (27%)

LC/MS (A): MS (ES+): 110 (M^++H), retention time 0.45 min

Example 37A

3-Furancarboximidamide hydrochloride



In analogy to the procedure for Example 5A, 10.0 g (71.4 mmol) ethyl 3-furoate and proportionate amounts of the other reagents are used.

Yield: 8.76 g (84%)

LC/MS (A): MS (ES+): 111 (M^++H), retention time 0.40 min

Example 38A

1-Methyl-1H-pyrrole-2-carboximidamide hydrochloride



In analogy to the procedure for Example 5A, 10.0 g (79.9 mmol) 1-methyl-1H-pyrrole-2-carboxylic acid and proportionate amounts of the other reagents are used.

Yield: 6.58 g (52%)

LC/MS (A): MS (ES+): 124 (M^++H), retention time 0.44 min

Example 39A

N-{1-[3-(5-Chloro-2-thienyl)-5-oxo-4,5-dihydro-1,2,4-triazin-6-yl]propyl}acetamide



In analogy to the procedure for Example 7A, 9,26 g (47,0 mmol) 5-chloro-2-thiophenecarboximidamide hydrochloride and proportionate amounts of the other reagents are used.

Yield: 6.8 g (34%)

^{1}H-NMR (DMSO-d_6, 300 MHz): δ = 0,91 (t, 3 H), 1,52-1,90 (m, 5 H, s bei 1,85), 4,87 (m, 1 H), 7,34 (d, 1 H), 7,94 (d, 1 H), 8,09 (d, 1 H, NH) ppm.

Example 40A

N-{1-[3-(1-Isoquinolinyl)-5-oxo-4,5-dihydro-1,2,4-triazin-6-yl]propyl}acetamide



In analogy to the procedure for Example 7A, 3,7 g (17,8 mmol) 1-isoquinoline-carboximidamide hydrochloride and proportionate amounts of the other reagents are used.

Yield: 1.88 g (33%)

LC/MS (method A): retention time 1.89 min., *m/z* 324 $[M+H]^+$

Example 41A

N-{1-[3-(3-Bromo-2-thienyl)-5-oxo-4,5-dihydro-1,2,4-triazin-6-yl]propyl}acetamide



In analogy to the procedure for Example 7A, 7,5 g (31,1 mmol) 3-bromo-2-thiophenecarboximidamide hydrochloride and proportionate amounts of the other reagents are used.

Yield: 2.34 g (21%)

^{1}H-NMR (CD_3OD, 500 MHz): δ = 0,93 (t, 3 H), 1,58-1,96 (m, 5 H, s bei 1,92), 4,97 (m, 1 H), 7,16 (d, 1 H), 7,79 (d, 1 H) ppm.

Example 42A

N-{1-[5-Oxo-3-(2-pyrazinyl)-4,5-dihydro-1,2,4-triazin-6-yl]propyl}acetamide



In analogy to the procedure for Example 7A, 3,0 g (18,9 mmol) 1,4-pyrazine-2-carboximidamide hydrochloride and proportionate amounts of the other reagents are used.

Yield: 1.88 g (36%)

^{1}H-NMR (DMSO-d_6, 200 MHz): δ = 0.9 (t, 3H), 1.6 (m, 1H), 1.8 (m, 1H), 1.9 (s, 3H), 4,9 (m, 1H), 8.2 (d, 1H), 8.7 (m, 1H), 8.9 (m, 1H), 9.4 (m, 1H) ppm.

Example 43A

N-{1-[3-(2-Methyl-1,3-thiazol-4-yl)-5-oxo-4,5-dihydro-1,2,4-triazin-6-yl]propyl}-acetamide



In analogy to the procedure for Example 7A, 4.5 g (25.3 mmol) 2-methyl-1,3-thiazole-4-carboximidamide hydrochloride and proportionate amounts of the other reagents are used.

Yield: 3.38 g (46%)

LC/MS (A): MS (ES+): 294 ($M+H^+$), retention time 1.51 min

Example 44A

N-{1-[5-Oxo-3-(1,3-thiazol-2-yl)-4,5-dihydro-1,2,4-triazin-6-yl]propyl}acetamide



In analogy to the procedure for Example 7A, 4.95 g (30.25 mmol) 1,3-thiazole-2-carboximidamide hydrochloride and proportionate amounts of the other reagents are used.

Yield: 3.61 g (43%)

^{1}H-NMR (DMSO-d_6, 400 MHz): δ = 0.9 (t, 3H), 1.6 (m, 1H), 1.8 (m, 1H), 1.9 (s, 3H), 4,9 (m, 1H), 8.2 (m, 2H), 14.6 (br.s, 1H) ppm.

Example 45A

N-{1-[3-(3,5-Difluoro-2-pyridinyl)-5-oxo-4,5-dihydro-1,2,4-triazin-6-yl]propyl}-acetamide



In analogy to the procedure for Example 7A, 5.00 g (25.8 mmol) 3,5-difluoro-2-pyridinecarboximidamide hydrochloride and proportionate amounts of the other reagents are used.

Yield: 2.19 g (27%)

^{1}H-NMR (DMSO-d_6, 300 MHz): δ = 0.9 (t, 3H), 1.6 (m, 1H), 1.8 (m, 1H), 1.9 (s, 3H), 4,9 (m, 1H), 8.1 (m, 1H), 8.2 (m, 1H), 8.7 (m, 1H), 14.1 (br.s, 1H) ppm.

Example 46A

N-{1-[3-(1,5-Dimethyl-1H-pyrrol-2-yl)-5-oxo-4,5-dihydro-1,2,4-triazin-6-yl]propyl}-acetamide



In analogy to the procedure for Example 7A, 5.80 g (33.4 mmol) of Example 34A and proportionate amounts of the other reagents are used.

Yield: 1.61 g (42%)

LC/MS (B): MS (ES+): 290 ($M+H^+$), retention time 2.54 min

Example 47A

N-{1-[3-(3-Bromo-2-pyridinyl)-5-oxo-4,5-dihydro-1,2,4-triazin-6-yl]propyl}-acetamide



In analogy to the procedure for Example 7A, 2.59 g (10.95 mmol) 3-bromo-2-pyridinecarboximidamide hydrochloride and proportionate amounts of the other reagents are used.

Yield: 2.19 g (27%)

^{1}H-NMR (DMSO-d_6, 200 MHz): δ = 0.9 (t, 3H), 1.6 (m, 1H), 1.8 (m, 1H), 1.9 (s, 3H), 4,9 (m, 1H), 7.6 (m, 1H), 8.2 (br. d, 1H), 8.4 (m, 1H), 8.7 (m. 1H), 14.3 (br.s, 1H) ppm.

Example 48A

N-{1-[3-(3-Chloro-2-pyridinyl)-5-oxo-4,5-dihydro-1,2,4-triazin-6-yl]propyl}-acetamide



In analogy to the procedure for Example 7A, 6.00 g (31.24 mmol) of Example 35A and proportionate amounts of the other reagents are used.

Yield: 3.40 g (35%)

^{1}H-NMR (DMSO-d_6, 200 MHz): δ = 0.9 (t, 3H), 1.6 (m, 1H), 1.8 (m, 1H), 1.9 (s, 3H), 4,9 (br. m, 1H), 7.7 (d/d, 1H), 8.2 (d/d, 1H), 8.7 (d/d, 1H), 14.3 (br.s, 1H) ppm.

Example 49A

N-{1-[5-Oxo-3-(1H-pyrrol-2-yl)-4,5-dihydro-1,2,4-triazin-6-yl]propyl}acetamide



In analogy to the procedure for Example 7A, 6.15 g (42.24 mmol) of Example 36A and proportionate amounts of the other reagents are used.

Yield: 3.98 g (36%)

LC/MS (A): MS (ES+): 262 ($M+H^+$), retention time 1.61 min

Example 50A

N-{1-[3-(3-Furyl)-5-oxo-4,5-dihydro-1,2,4-triazin-6-yl]propyl}acetamide



In analogy to the procedure for Example 7A, 8.76 g (59.8 mmol) of Example 37A and proportionate amounts of the other reagents are used.

Yield: 4.26 g (27%)

LC/MS (A): MS (ES+): 263 ($M+H^+$), retention time 1.55 min

Example 51A

N-{1-[3-(1-Methyl-1H-pyrrol-2-yl)-5-oxo-4,5-dihydro-1,2,4-triazin-6-yl]propyl}-acetamide



In analogy to the procedure for Example 7A, 6.58 g (41.22 mmol) of Example 38A and proportionate amounts of the other reagents are used.

Yield: 2.88 g (25%)

LC/MS (A): MS (ES+): 276 ($M+H^+$), retention time 1.73 min

Example 52A

N-{1-[5-Oxo-3-(3-pyridinyl)-4,5-dihydro-1,2,4-triazin-6-yl]propyl}acetamide



In analogy to the procedure for Example 7A, 15,0 g (0,1 mol) 3-pyridincarboximidamide hydrochloride and proportionate amounts of the other reagents are used.

Yield: 13.1 g (50%)

^{1}H-NMR (d_6-DMSO, 200 MHz): δ = 0.9 (t, 3H), 1.6 (m, 2H), 1.8 (m, 4H); 4.9 (m, 1H); 7.6 (m, 1H); 8.2 (m, 1H); 8.4 (m, 1H), 8.8 (m, 1H) , 9.2 (m, 1H), 14.5 (bs, 1H) ppm.

Example 53A

N-{1-[5-Oxo-3-(2-pyridinyl)-4,5-dihydro-1,2,4-triazin-6-yl]propyl}acetamide



In analogy to the procedure for Example 7A, 6,0 g (38,1 mmol) 2-pyridincarboximidamide hydrochloride and proportionate amounts of the other reagents are used.

Yield: 5.6 g (54%)

^{1}H-NMR (d_6-DMSO, 200 MHz): δ = 0.9 (t, 3H), 1.7 (m, 2H), 1.9 (s, 3H); 4.9 (m, 1H); 7.5 (bs); 7.7 (m, 1H); 8.2 (m, 2H), 8.8 (m, 1H) ppm.

Example 54A

N-{1-[5-Oxo-3-(4-pyridinyl)-4,5-dihydro-1,2,4-triazin-6-yl]propyl}acetamide



In analogy to the procedure for Example 7A, 10,0 g (63,5 mmol) 4-pyridincarboximidamide hydrochloride and proportionate amounts of the other reagents are used.

Yield: 10.5 g (61%)

^{1}H-NMR (d_6-DMSO, 200 MHz): δ = 1,0 (t, 3H), 1.8 (m, 2H), 2.0 (s, 3H); 5.0 (m, 1H); 7.8 (m, 2H); 8.1 (m, 2H), 8.8 (m, 2H) ppm.

Example 55A

N-{1-[3-(2,5-Dichloro-1,3-thiazol-4-yl)-5-oxo-4,5-dihydro-1,2,4-triazin-6-yl]propyl}-acetamide



In analogy to the procedure for Example 7A, 5,0 g (21,5 mmol) 2,5-dichloro-1,3-thiazole-4-carboximidamide hydrochloride and proportionate amounts of the other reagents are used.

Yield: 600 mg (8%)

^{1}H-NMR (d_6-DMSO, 300 MHz): δ = 0,9 (t, 3H), 1.6 (m, 2H), 1.9 (s, 3H); 4.9 (m, 1H); 8.1 (m, 1H), 14.2 (bs, 1H) ppm.

Example 56A

N-{1-[3-(2-Furyl)-5-oxo-4,5-dihydro-1,2,4-triazin-6-yl]propyl}acetamide



In analogy to the procedure for Example 7A, 5,0 g (21,5 mmol) 2-furan-carboximidamide hydrochloride and proportionate amounts of the other reagents are used.

Yield: 2.8 g (31%)

^{1}H-NMR (d_6-DMSO, 200 MHz): δ = 0,9 (t, 3H), 1.6 (m, 1H), 1.8 (m, 1H), 1.9 (s, 3H); 4.9 (m, 1H); 6.8 (m, 1H); 7.5 (m, 1H), 8.1 (m, 2H); 14.1 (bs, 1H) ppm.

Example 57A

6-(1-Aminopropyl)-3-(5-chloro-2-thienyl)-1,2,4-triazin-5(4H)-one



In analogy to the procedure for Example 11A, 1,7 g (2,14 mmol) N-{1-[3-(5-chloro-2-thienyl)-5-oxo-4,5-dihydro-1,2,4-triazin-6-yl]propyl}acetamide and proportionate amounts of the other reagents are used.

Yield: 0.35 g (61%)

^{1}H-NMR (CD_3OD, 400 MHz): δ = 1,01 (t, 3 H), 1,90-2,19 (m, 2 H), 4,45 (t, 1 H), 7,01 (d, 1 H), 7,68 (d, 1 H) ppm.

Example 58A

6-(1-Aminopropyl)-3-(1-isoquinolinyl)-1,2,4-triazin-5(4H)-one



In analogy to the procedure for Example 11A, 1,88 g (3,66 mmol) N-{1-[3-(1-isoquinolinyl)-5-oxo-4,5-dihydro-1,2,4-triazin-6-yl]propyl}acetamide and proportionate amounts of the other reagents are used.

Yield: 0.5 g (48%)

^{1}H-NMR (CD_3OD, 400 MHz): δ = 1,08 (t, 3 H), 1,99-2,27 (m, 2 H), 4,59 (t, 1 H), 7,66 (t, 1 H), 7,81 (t, 1 H), 7,94 (d, 1 H), 8,02 (d, 1 H), 8,20 (d, 1 H), 8,53 (d, 1 H) ppm.

Example 59A

6-(1-Aminopropyl)-3-(3-bromo-2-thienyl)-1,2,4-triazin-5(4H)-one



In analogy to the procedure for Example 11A, 2,33 g (6,52 mmol) N-{1-[3-(3-bromo-2-thienyl)-5-oxo-4,5-dihydro-1,2,4-triazin-6-yl]propyl}acetamide and proportionate amounts of the other reagents are used.

Yield: 1.04 g (51%)

^{1}H-NMR (CD_3OD, 400 MHz): δ = 1,02 (t, 3 H), 1,92-2,21 (m, 2 H), 4,48 (t, 1 H), 7,10 (d, 1 H), 7,56 (d, 1 H) ppm.

Example 60A

6-(1-Aminopropyl)-3-(2-pyrazinyl)-1,2,4-triazin-5(4H)-one



In analogy to the procedure for Example 11A, 1.88 g (6,9 mmol) of Example 42A and proportionate amounts of the other reagents are used.

Yield: 1.5 g (93%)

LC/MS (A): MS (ES+): 233 ($M+H^+$), retention time 0.37 min

Example 61A

6-(1-Aminopropyl)-3-(2-methyl-1,3-thiazol-4-yl)-1,2,4-triazin-5(4H)-one



In analogy to the procedure for Example 11A, 3.35 g (11.42 mmol) of Example 43A and proportionate amounts of the other reagents are used.

Yield: 1.51 g (53%)

LC/MS (A): MS (ES+): 252 ($M+H^+$), retention time 0.48 min

Example 62A

6-(1-Aminopropyl)-3-(1,3-thiazol-2-yl)-1,2,4-triazin-5(4H)-one



In analogy to the procedure for Example 11A, 3.60 g (12.9 mmol) of Example 44A and proportionate amounts of the other reagents are used.

Yield: 1.76 g (57%)

^{1}H-NMR (DMSO-d_6, 200 MHz): δ = 0.9 (t, 3H), 1.9 (m, 2H), 4,3 (t, 1H), 7.8 (d, 1H), 7.9 (d, 1H), 8.2 (br. m, 3H).

Example 63A

6-(1-Aminopropyl)-3-(3,5-difluoro-2-pyridinyl)-1,2,4-triazin-5(4H)-one



In analogy to the procedure for Example 11A, 2.15 g (6.9 mmol) of Example 45A and proportionate amounts of the other reagents are used.

Yield: 0.68 g (37%)

LC/MS (A): MS (ES+): 268 ($M+H^+$), retention time 0.44 min

Example 64A

6-(1-Aminopropyl)-3-(1,5-dimethyl-1H-pyrrol-2-yl)-1,2,4-triazin-5(4H)-one



In analogy to the procedure for Example 11A, 3.67 g (12.7 mmol) of Example 46A and proportionate amounts of the other reagents are used.

Yield: 1.69 g (54%)

LC/MS (A): MS (ES+): 248 ($M+H^+$), retention time 1.31 min

Example 65A

6-(1-Aminopropyl)-3-(3-bromo-2-pyridinyl)-1,2,4-triazin-5(4H)-one



In analogy to the procedure for Example 11A, 1.60 g (4.54 mmol) of Example 47A and proportionate amounts of the other reagents are used.

Yield: 0.48 g (34%)

^{1}H-NMR (DMSO-d_6, 300 MHz): δ = 0.9 (t, 3H), 1.9 (m, 1H), 2.0 (m, 1H), 4,3 (t, 1H), 7.4 (m, 1H), 8.0 (br. s, 3H), 8.1 (m, 1H), 8.6 (m, 1H) ppm.

Example 66A

6-(1-Aminopropyl)-3-(3-chloro-2-pyridinyl)-1,2,4-triazin-5(4H)-one



In analogy to the procedure for Example 11A, 3.40 g (11.05 mmol) of Example 48A and proportionate amounts of the other reagents are used.

Yield: 1.24 g (42%)

^{1}H-NMR (DMSO-d_6, 300 MHz): δ = 0.9 (t, 3H), 1.9 (m, 2H), 4,3 (t, 1H), 7.5 (d/d, 1H), 8.0 (d/d, 1H), 8.0 (br.s, 3H), 8.5 (d/d, 1H) ppm.

Example 67A

6-(1-Aminopropyl)-3-(1H-pyrrol-2-yl)-1,2,4-triazin-5(4H)-one



In analogy to the procedure for Example 11A, 3.98 g (15.23 mmol) of Example 49A and proportionate amounts of the other reagents are used.

Yield: 1.82 g (54%)

^{1}H-NMR (DMSO-d_6, 300 MHz): δ = 0.9 (t, 3H), 1.9 (m, 1H), 2.0 (m, 1H), 4,2 (t, 1H), 6.2 (m, 1H, 6.9 (m, 2H), 8.4 (br. s, 3H), 11.6 (br. s, 1H) ppm.

Example 68A

6-(1-Aminopropyl)-3-(3-furyl)-1,2,4-triazin-5(4H)-one



In analogy to the procedure for Example 11A, 4.26 g (16.24 mmol) of Example 50A and proportionate amounts of the other reagents are used. The product is used for the next step without further purification.

LC/MS (B): MS (ES+): 221 ($M+H^+$), retention time 0.35 min

Example 69A

6-(1-Aminopropyl)-3-(1-methyl-1H-pyrrol-2-yl)-1,2,4-triazin-5(4H)-one



In analogy to the procedure for Example 11A, 2.88 g (10.46 mmol) of Example 51A and proportionate amounts of the other reagents are used. The product is used for the next step without further purification.

LC/MS (B): MS (ES+): 234 ($M+H^+$), retention time 0.40 min

Example 70A

6-(1-Aminopropyl)-3-(3-pyridinyl)-1,2,4-triazin-5(4H)-one



In analogy to the procedure for Example 11A, 3,40 g (10 mmol) of Example 52A and proportionate amounts of the other reagents are used. The compound is used without further purification.

LC/MS (A): MS (ESI): 232 ($M+H^+$), retention time 0.37 min

^{1}H-NMR (d_6-DMSO, 200 MHz): δ = 0,9 (t, 3H), 1.9 (m, 2H), 4.3 (m, 1H), 7.5 (br. s), 8.1-9.4 (m) ppm.

Example 71A

6-(1-Aminopropyl)-3-(2-pyridinyl)-1,2,4-triazin-5(4H)-one



In analogy to the procedure for Example 11A, 7,60 g (27,8 mmol) of Example 53A and proportionate amounts of the other reagents are used. The compound is used without further purification.

LC/MS (A): MS (ESI): 232 ($M+H^+$), retention time 0.35 min

^{1}H-NMR (d_6-DMSO, 200 MHz): δ = 0,9 (t, 3H), 1.9 (m, 2H), 4.3 (m, 1H), 7.8 (br. s), 8.0 (m, 1H), 8.3 (m, 1H), 8.8 (m, 1H) ppm.

Example 72A

6-(1-Aminopropyl)-3-(4-pyridinyl)-1,2,4-triazin-5(4H)-one



In analogy to the procedure for Example 11A, 4,50 g (16,5 mmol) of Example 54A and proportionate amounts of the other reagents are used.

Yield: 3.1 g (81%)

LC/MS (A): MS (ESI): 232 ($M+H^+$), retention time 0.34 min

^{1}H-NMR (d_6-DMSO, 200 MHz): δ = 0,9 (t, 3H), 1.9 (m, 2H), 4.3 (m, 1H), 7.5 (br. s), 8.1 (m, 2H), 8.7 (m, 2H) ppm.

Example 73A

6-(1-Aminopropyl)-3-(2,5-dichloro-1,3-thiazol-4-yl)-1,2,4-triazin-5(4H)-one



In analogy to the procedure for Example 11A, 200 mg (0,57 mmol) of Example 55A and proportionate amounts of the other reagents are used.

Yield: 150 mg (85%)

LC/MS (B): MS (ESI): 306 ($M+H^+$), retention time 0.35 min

Example 74A

6-(1-Aminopropyl)-3-(2-furyl)-1,2,4-triazin-5(4H)-one



In analogy to the procedure for Example 11A, 2,60 g (9,91 mmol) of Example 56A and proportionate amounts of the other reagents are used. The compound is used without further purification.

LC/MS (A): MS (ESI): 221 ($M+H^+$), retention time 0.33 min

^{1}H-NMR (d_6-DMSO, 200 MHz): δ = 0.8 (t, 3H), 1.7 (m, 2H), 3.7 (m, 1H), 6.5 (m, 1H), 6.9 (m, 1H), 7.7 (m, 1H) ppm.

Example 75A

N-{1-[5-Oxo-3-(2-thienyl)-4,5-dihydro-1,2,4-triazin-6-yl]propyl}-3-(trifluoromethyl)-cyclohexanecarboxamide



83 mg (0,42 mmol, 1 equiv.) 3-trifluoromethylcyclohexanecarboxylic acid are suspended in dichloromethane at 0°C and 62 mg (0,456 mmol, 1,05 equiv.) 1-hydroxy-1H-benzotriazol and 87 mg (0,456 mmol, 1,05 equiv.) 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride are consecutively added. After stirring at room temperature for 30 min, 100 mg (0,42 mmol) of Example 14A are added. The reaction mixture is stirred at room temperature for 2 hours. The mixture is diluted with dichloromethane, washed twice with 1N sulfuric acid and once with saturated sodium bicarbonate solution, dried over magnesium sulfate and evaporated to dryness *in vacuo*. The product is used without further purification.

Yield: 160 mg (91%)

LC/MS (B): MS (ESI): 415 ($M+H^+$), retention time 3.63 min

Example 76A

4-Methyl-N-{1-[5-oxo-3-(2-thienyl)-4,5-dihydro-1,2,4-triazin-6-yl]propyl}cyclohexanecarboxamide



In analogy to the procedure for Example 75A, 103 mg (0,43 mmol) of Example 14A, 62 mg (0,43 mmol) 4-methylcyclohexanecarboxylic acid and proportionate amounts of the other reagents are used.

Yield: 150 mg (95%)

LC/MS (B): MS (ESI): 361 ($M+H^+$), retention time 3.59 min

Example 77A

2-Cyclohexyl-N-{1-[5-oxo-3-(2-thienyl)-4,5-dihydro-1,2,4-triazin-6-yl]propyl}-acetamide



In analogy to the procedure for Example 15A, 100 mg (0,42 mmol) of Example 14A, 70 mg (0,47 mmol) cyclohexylacetyl chloride and proportionate amounts of the other reagents are used.

Yield: 150 mg (98%)

LC/MS (B): MS (ESI): 361 ($M+H^+$), retention time 3.51 min

Example 78A

1,4-Dimethyl-N-{1-[5-oxo-3-(2-thienyl)-4,5-dihydro-1,2,4-triazin-6-yl]propyl}cyclo-hexanecarboxamide



In analogy to the procedure for Example 15A, 100 mg (0,42 mmol) of Example 14A, 80 mg (0,47 mmol) 1,4-dimethylcyclohexanecarbonyl chloride and proportionate amounts of the other reagents are used.

Yield: 150 mg (94%)

LC/MS (B): MS (ESI): 375 ($M+H^+$), retention time 3.88 min

Example 79A

N-[1-(3-(2-Thienyl)-5-oxo-4,5-dihydro-1,2,4-triazin-6-yl)propyl]-1-adamantane-carboxamide



In analogy to the procedure for Example 15A, 100 mg (0,43 mmol) of Example 14A, 95 mg (0,48 mmol) 1-adamantanecarbonyl chloride and proportionate amounts of the other reagents are used.

Yield: 160 mg (92%)

LC/MS (B): MS (ESI): 399 ($M+H^+$), retention time 3.90 min

Example 80A

4-tert-Butyl-N-{1-[5-oxo-3-(3-pyridinyl)-4,5-dihydro-1,2,4-triazin-6-yl]propyl}-cyclohexanecarboxamide



In analogy to the procedure for Example 15A, 250 mg (1,08 mmol) of Example 70A, 240 mg (1,19 mmol) 4-tert-butylcyclohexanecarbonyl chloride and proportionate amounts of the other reagents are used.

Yield: 200 mg (47%)

LC/MS (B): MS (ESI): 398 ($M+H^+$), retention time 3.79 min

Example 81A

4-cis-tert-Butyl-N-{1-[5-oxo-3-(2-pyridinyl)-4,5-dihydro-1,2,4-triazin-6-yl]propyl}-cyclohexanecarboxamide



In analogy to the procedure for Example 15A, 200 mg (0,86 mmol) of Example 71A, 190 mg (0,95 mmol) 4-cis-tert-butylcyclohexanecarbonyl chloride and proportionate amounts of the other reagents are used.

Yield: 300 mg (87%)

LC/MS (B): MS (ESI): 398 ($M+H^+$), retention time 4.21 min

Example 82A

4-cis-tert-Butyl-N-{1-[5-oxo-3-(4-pyridinyl)-4,5-dihydro-1,2,4-triazin-6-yl]propyl}-cyclohexanecarboxamide



In analogy to the procedure for Example 15A, 200 mg (0,86 mmol) of Example 72A, 190 mg (0,95 mmol) 4-cis-tert-butylcyclohexanecarbonyl chloride and proportionate amounts of the other reagents are used.

Yield: 300 mg (87%)

LC/MS (B): MS (ESI): 398 ($M+H^+$), retention time 3.78 min

Example 83A

4-tert-Butyl-N-{1-[3-(2,5-dichloro-1,3-thiazol-4-yl)-5-oxo-4,5-dihydro-1,2,4-triazin-6-yl]propyl}cyclohexanecarboxamide



In analogy to the procedure for Example 15A, 150 mg (0,49 mmol) of Example 73A, 110 mg (0,54 mmol) 4-cis-tert-butylcyclohexanecarbonyl chloride and proportionate amounts of the other reagents are used.

Yield: 100 mg (43%)

MS (ESI): 473 ($M+H^+$)

Example 84A

4-tert-Butyl-N-{1-[3-(2-furyl)-5-oxo-4,5-dihydro-1,2,4-triazin-6-yl]propyl}-cyclohexanecarboxamide



In analogy to the procedure for Example 15A, 250 mg (1,14 mmol) of Example 74A, 250 mg (1,25 mmol) 4-cis-tert-butylcyclohexanecarbonyl chloride and proportionate amounts of the other reagents are used.

Yield: 300 mg (68%)

LC/MS (B): MS (ESI): 387 ($M+H^+$), retention time 4.00 min

Example 85A

cis-4-*tert*-Butylcyclohexanecarboxylic acid



A preparative HPLC separation of cis- and trans-4-*tert*-butylcyclohexanecarboxylic acid was carried out under the following conditions:

Feed:	10 g isomeric mixture of cis- and trans-4-*tert*-butyl-cyclo-hexanecarboxylic acid dissolved in 500 ml iso-hexane (80%) / *tert*-butylmethylether (20%)
Column:	330 x 100 mm; Self Packing Device NW 100; Merck
Stationary phase:	LiChrospher Si 60, 12 µm, Merck

Mobile phase:	iso-hexane / *tert*-butylmethylether (4/1 v/v) + 0.25 vol-% acetic acid
Flow:	150 ml/min
Injection volume:	70 ml (= 1.4 g compound)
Wave length:	210 nm
Temperature:	25°C

The sample run on this column was repeatedly injected every 30 minutes. The cis-isomer is the first eluting compound.

cis-isomer:

mp: 118°C

^{1}H-NMR (300 MHz, DMSO): δ = 0.9 (t, 3 H), 1.0 (m, 3 H), 1.4 (m, 2 H), 1.6 (m, 1 H), 2.1 (m, 2 H), 2.5 (m, 1 H), 12.0 (s, 1 H) ppm.

trans-isomer:

mp: 172°C

^{1}H-NMR (300 MHz, DMSO): δ = 0.9 (t, 3 H), 1.0 (m, 3 H), 1.3 (m, 2 H), 1.7 (m, 1 H), 1.9 (m, 2 H), 2.1 (m, 1 H), 11.9 (s, 1 H) ppm.

Example 86A

cis-4-*tert*-Butylcyclohexanecarbonyl chloride



2.0 g (10.85 mmol) cis-4-*tert*-Butylcyclohexanecarboxylic acid are dissolved in 50 ml dichloromethane, 1.65 g (13.02 mmol) ethanedioyl dichloride are added and the solution is stirred at room temperature for one hour. The mixture is then stirred at reflux for two hours and, after cooling down to room temperature, evaporated to dryness *in vacuo*. The residue is then dissolved in toluene two times and again evaporated to dryness *in vacuo*. The residue is used in the next step without further purification.

Preparation Examples

Example 1

7-Cyclobutyl-5-ethyl-2-(2-phenyl-1,3-thiazol-4-yl)imidazo[5,1-f][1,2,4]triazin-4(3H)-one



202 mg (0,51 mmol, 1 equiv.) of Example 16A are suspended in 10 ml dichloroethane, and 117 mg (0,77 mmol, 1,5 equiv.) phosphoroxychloride are added. The mixture is stirred at reflux for 3 hours. After cooling down to room temperature, ethyl acetate and saturated $NaHCO_3$ (aq) are added. The organic phase is washed with saturated $NaHCO_3$ (aq), water and brine, dried over sodium sulfate and evaporated to dryness *in vacuo*. The product is purified by chromatography (flash or column chromatography or preparative HPLC).

Yield: 108 mg (56%)

^{1}H-NMR (DMSO-d_6, 300 MHz): δ = 1,2 (t, 3H), 2,0 (m, 2H), 2,4 (m, 4H), 2,9 (q, 2H, 4,0 (m, 1H, 7,5 (m, 3H), 8,2 (m, 2H), 8,5 (s, 1H), 11,7 (s, 1H) ppm.

Example 2

7-Cyclopentyl-5-ethyl-2-(2-phenyl-1,3-thiazol-4-yl)imidazo[5,1-f][1,2,4]triazin-4(3H)-one



In analogy to the procedure for Example 1, 155 mg (0,38 mmol) of Example 15A, 87 mg (0,57 mmol) phosphoric trichloride are stirred at reflux for 3 hours, proportionate amounts of the solvents are used.

Yield: 80 mg (54%)

^{1}H-NMR (DMSO-d_6, 300 MHz): δ = 1,2 (t, 3H), 1,7 (m, 2H), 1,8 (m, 4H), 2,1 (m,2H), 2,9 (q, 2H), 3,6 (m, 1H), 7,5 (m, 3H), 8,2 (m, 2H), 8,5 (s, 1H), 11,7 (s, 1H) ppm.

Example 3

7-Cyclopentyl-5-ethyl-2-(3-thienyl)imidazo[5,1-f][1,2,4]triazin-4(3H)-one



In analogy to the procedure for Example 1, 550 mg (1,65 mmol) of Example 17A, 380 mg (2,48 mmol) phosphoric trichloride are stirred at reflux for 3 hours, proportionate amounts of the solvents are used.

Yield: 80 mg (15%)

^{1}H-NMR (DMSO-d_6, 200 MHz): δ = 1,2 (t, 3H), 1,8 (m, 6H), 2,1 (m,2H), 2,9 (q, 2H), 3,6 (m, 1H), 7,7 (m, 2H), 8,5 (m, 1H), 11,7 (s, 1H) ppm.

Example 4

7-Cyclobutyl-5-ethyl-2-(3-thienyl)imidazo[5,1-f][1,2,4]triazin-4(3H)-one



In analogy to the procedure for Example 1, 530 mg (1,66 mmol) of Example 18A, 383 mg (2,50 mmol) phosphoric trichloride are stirred at reflux for 3 hours, proportionate amounts of the solvents are used.

Yield: 47 mg (9%)

^{1}H-NMR (DMSO-d_6, 200 MHz): δ = 1,2 (t, 3H), 1,8 (m, 1H), 2,1 (m, 1H), 2,4 (m, 4H), 2,9 (q, 2H), 4,0 (m, 1H), 7,7 (m, 2H), 8,5 (m, 1H), 11,8 (s, 1H) ppm.

Example 5 and Example 6

7-(4-tert-Butylcyclohexyl)-5-ethyl-2-(3-thienyl)imidazo[5,1-f][1,2,4]triazin-4(3H)-one



In analogy to the procedure for Example 1, 680 mg (1,69 mmol) of Example 19A, 389 mg (2,53 mmol) phosphoric trichloride are stirred at reflux for 3 hours, proportionate amounts of the solvents are used. The isomers are separated by chromatography.

Yield: 18 mg (3%) cis-isomer
90 mg (14%) trans-isomer

cis-isomer (Example 5):

^{1}H-NMR (DMSO-d_6, 300 MHz): δ = 0,8 (s, 9H), 1,1 (m, 1H), 1,2 (t, 3H), 1,6 (m, 3H), 1,7 (m, 3H), 2,2 (m, 2H), 2,9 (m, 2H), 3,5 (m, 1H), 7,7 (m, 1H), 7,7 (m, 1H), 8,5 (m, 1H), 11,7 (s, 1H) ppm.

trans-isomer (Example 6):

^{1}H-NMR (DMSO-d_6, 300 MHz): δ = 0,9 (s, 9H), 1,1 (m, 2H), 1,2 (t, 3H), 1,6 (m, 2H), 1,8 (m, 2H), 2,0 (m, 2H), 2,9 (m, 2H), 3,1 (m, 1H), 7,7 (m, 1H), 7,7 (m, 2H), 11,8 (s, 1H) ppm.

Example 7

7-Cyclopentyl-5-ethyl-2-(2-quinolinyl)imidazo[5,1-f][1,2,4]triazin-4(3H)-one



In analogy to the procedure for Example 1, 280 mg (0,73 mmol) N-{1-[5-oxo-3-(2-quinolinyl)-4,5-dihydro-1,2,4-triazin-6-yl]propyl}cyclopentanecarboxamide, 560 mg (3,64 mmol) phosphoric trichloride are stirred at reflux for 3 hours, proportionate amounts of the solvents are used.

Yield: 73 mg (28%)

^{1}H-NMR (400 MHz, CD_3OD): δ = 1,22 (t, 3 H), 1,57-2,19 (m, 8 H), 2,92 (q, 2 H), 3,69 (quint, 1 H), 7,58-7,63 (t, 1 H), 7,72-7,79 (t, 1 H), 7,92 (d, 1 H), 8,15 (d, 1 H), 8,29 (d, 1 H), 8,40 (d, 1 H) ppm.

Example 8

7-Cyclopentyl-5-ethyl-2-(4-pyridyl)imidazo [5,1-f]triazin-4(3H)-one



In analogy to the procedure for Example 1, 25 mg (0,37 mmol) of Example 21A, 56 mg (0,37 mmol) phosphoric trichloride are stirred at reflux for 2 hours, proportionate amounts of the solvents are used.

Yield: 125 mg (100%)

LC/MS (A): MS (ESI): 310 ($M+H^+$), retention time 3.00 min.

Example 9

7-Cyclopentyl-2-(4,6-dimethyl-2-pyridinyl)-5-ethylimidazo[5,1-f][1,2,4]triazin-4(3H)-one



In analogy to the procedure for Example 1, 2,25 g (6,33 mmol) of Example 22A, 971 mg (6,33 mmol) phosphoric trichloride are stirred at reflux for 2 hours, proportionate amounts of the solvents are used.

Yield: 120 mg (6%)

LC/MS (A): MS (ESI): 337 ($M+H^+$), retention time 4.30 min.

Example 10

7-Cyclopentyl-5-ethyl-2-(3-pyridinyl)imidazo[5,1-f][1,2,4]triazin-4(3H)-one



In analogy to the procedure for Example 1, 2,25 g (6,33 mmol) of Example 23A, 971 mg (6,33 mmol) phosphoric trichloride are stirred at reflux for 2 hours, proportionate amounts of the solvents are used.

Yield: 120 mg (6%)

^{1}H-NMR (300 MHz, DMSO): δ = 12.00 (br. s, 1H), 9.10 (d, J=2Hz, 1H), 8.75 (m, 1H), 8.30 (m, 1H), 7.60 (dd, J=5Hz, J=7Hz, 1H), 3.60 (m, 1H), 2.90 (q, J=7Hz, 2H), 2.20-1.60 (m, 8H), 1.25 (t, J=7Hz, 3H) ppm.

Example 11

7-Cyclopentyl-5-ethyl-2-(2-thienyl)imidazo[5,1-f][1,2,4]triazin-4(3H)-one



In analogy to the procedure for Example 1, 500 mg (1,50 mmol) of Example 24A, 384 mg (1,50 mmol) phosphoric trichloride are stirred at reflux for 2 hours, proportionate amounts of the solvents are used.

Yield: 390 mg (82%)

^{1}H-NMR (300 MHz, DMSO): δ = 12.10 (br. s, 1H), 8.10 (d, J=3Hz, 1H), 7.85 (d, J=5Hz, 1H), 7.20 (dd, J=3Hz, J=5Hz, 1H), 3.50 (m, 1H), 2.90 (q, J=7Hz, 2H), 2.20-1.60 (m, 8H), 1.20 (t, J=7Hz, 3H) ppm.

Example 12

7-Cyclopentyl-5-ethyl-2-(2-pyridinyl)imidazo[5,1-f][1,2,4]triazin-4(3H)-one



In analogy to the procedure for Example 1, 940 mg (2,87 mmol) of Example 25A, 440 mg (2,87 mmol) phosphoric trichloride are stirred at reflux for 4 hours, proportionate amounts of the solvents are used.

Yield: 440 mg (49%)

^{1}H-NMR (300 MHz, DMSO): δ = 11.20 (br. s, 1H), 8.80 (d, J=2Hz, 1H), 8.25 (d, J=7Hz, 1H), 8.05 (m, 1H), 7.65 (m, 1H), 3.60 (m, 1H), 2.90 (q, J=7Hz, 2H), 2.20-1.60 (m, 8H), 1.20 (t, J=7Hz, 3H) ppm.

Example 13

7-Cyclopentyl-5-ethyl-2-(2-furyl)imidazo[5,1-f][1,2,4]triazin-4(3H)-one



In analogy to the procedure for Example 1, 380 mg (1,20 mmol) of Example 26A, 184 mg (1,20 mmol) phosphoric trichloride are stirred at reflux for 4 hours, proportionate amounts of the solvents are used.

Yield: 100 mg (28%)

^{1}H-NMR (300 MHz, DMSO): δ = 12.00 (br. s, 1H), 8.00 (m, 1H), 7.55 (m, 1H), 6.75 (m, 1H), 3.50 (m, 1H), 2.85 (q, J=7Hz, 2H), 2.20-1.60 (m, 8H), 1.20 (t, J=7Hz, 3H) ppm.

Example 14

7-(cis-4-tert-Butylcyclohexyl)-5-ethyl-2-(2-thienyl)imidazo[5,1-f][1,2,4]triazin-4(3H)-one



1,6 g (3,98 mmol, 1 equiv.) of Example 27A are suspended in 28 ml dichloroethane, and 2,27 g (14,8 mmol, 4 equiv.) phosphoroxychloride are added. The mixture is stirred at reflux for 4 hours. After cooling down to room temperature, dichloromethane is added and the organic phase is quenched with water, washed with water, dried over magnesium sulfate and evaporated to dryness *in vacuo*. The solid residue is washed with diethyl ether, filtered and dried.

Yield: 0.67 g (45%)

^{1}H-NMR (300 MHz, DMSO): δ = 0.83 (s, 9H); 1.01-1.13 (m, 1H); 1.18 (t, 3H); 1.49-1.75 (m, 6H); 2.20 (m, 2H), 2.88 (q, 2H); 3.47 (m, 1H); 7.20 (dd, 1H); 7.80 (dd, 1H); 8.08 (dd, 1H); 11.92 (s, 1H) ppm.

Example 15

7-Cyclobutyl-5-ethyl-2-(2-thienyl)imidazo[5,1-f][1,2,4]triazin-4(3H)-one



In analogy to the procedure for Example 1, 140 mg (0,44 mmol) of Example 28A, 165 mg (1,07 mmol) phosphoric trichloride are stirred at reflux for 3 hours, proportionate amounts of the solvents are used.

Yield: 31 mg (23%)

^{1}H-NMR (300 MHz, DMSO): δ = 1.24 (t, 3H); 1.88-2.52 (t, 6H); 2.88 (q, 2H); 3.93 (m, 1H); 7.22 (m, 1H); 7.84 (dd, 1H); 8.08 (dd, 1H); 12.01 (s, 1H) ppm.

Example 16

7-(trans-4-tert-Butylcyclohexyl)-5-ethyl-2-(2-thienyl)imidazo[5,1-f][1,2,4]triazin-4(3H)-one



In analogy to the procedure for Example 1, 580 mg (1,44 mmol) of Example 29A, 820 mg (5,36 mmol) phosphoric trichloride are stirred at reflux for 4 hours, proportionate amounts of the solvents are used.

Yield: 85 mg (15%)

^{1}H-NMR (300 MHz, DMSO): δ = 0.89 (s, 9H); 1.12 (m, 2H); 1.22 (m, 4H); 1.62 (m, 2H); 1.87 (m, 2H); 2.03 (m, 2H); 2.87 (q, 2H); 2.86-3.07 (m, 1H); 7.21 (dd, 1H); 7.82 (dd, 1H); 8.08 (dd, 1H); 11.97 (s, 1H) ppm.

Example 17

5-Ethyl-7-isobutyl-2-(2-thienyl)imidazo[5,1-f][1,2,4]triazin-4(3H)-one



In analogy to the procedure for Example 1, 270 mg (0,84 mmol) of Example 30A, 235 mg (1.53 mmol) phosphoric trichloride are stirred at reflux for 4 hours, proportionate amounts of the solvents are used.

Yield: 4.5 mg (2%)

^{1}H-NMR (300 MHz, DMSO): δ = 0.94 (d, 6H); 1.23 (t, 3H); 2.17 (m, 1H); 2.79-2.97 (m, 4H); 7.21 (dd, 1H); 7.82 (dd, 1H); 8.10 (dd, 1H); 12.00 (s, 1H) ppm.

Example 18

2-(5-Chloro-2-thienyl)-7-cyclopentyl-5-ethylimidazo[5,1-f][1,2,4]triazin-4(3H)-one



In analogy to the procedure for Example 1, 203 mg (0,55 mmol) crude N-{1-[3-(5-chloro-2-thienyl)-5-oxo-4,5-dihydro-1,2,4-triazin-6-yl]propyl}cyclopentanecarboxamide, 127 mg (0,83 mmol) phosphoric trichloride are stirred at reflux for 3 hours, proportionate amounts of the solvents are used.

Yield: 67 mg (35%)

^{1}H-NMR (400 MHz, CD_3OD): δ = 1,28 (t, 3 H), 1,56-2,18 (m, 8 H), 2,96 (q, 2 H), 3,60 (quint, 1 H), 7,09 (d, 1 H), 7,72 (d, 1 H) ppm.

Example 19

cis-7-(4-tert-Butylcyclohexyl)-2-(5-chloro-2-thienyl)-5-ethylimidazo[5,1-f][1,2,4]-triazin-4(3H)-one



In analogy to the procedure for Example 1, 322 mg (0,74 mmol) crude cis-4-tert-butyl-N-{1-[3-(5-chloro-2-thienyl)-5-oxo-4,5-dihydro-1,2,4-triazin-6-yl]propyl}-cyclohexanecarboxamide, 169 mg (1,10 mmol) phosphoric trichloride are stirred at reflux for 3 hours, proportionate amounts of the solvents are used.

Yield: 72 mg (23%)

^{1}H-NMR (400 MHz, CD_3OD): δ = 0,85 (s, 9 H), 0,96-2,40 (m, 12 H, t at 1,27), 2,96 (q, 2 H), 3,48 (m, 1 H), 7,11 (d, 1 H), 7,79 (d, 1 H) ppm.

Example 20

7-Cyclopentyl-5-ethyl-2-(1-isoquinolinyl)imidazo[5,1-f][1,2,4]triazin-4(3H)-one



In analogy to the procedure for Example 1, 402 mg (1,07 mmol) crude N-{1-[3-(1-isoquinolinyl)-5-oxo-4,5-dihydro-1,2,4-triazin-6-yl]propyl}cyclopentanecarboxamide, 245 mg (1,60 mmol) phosphoric trichloride are stirred at reflux for 3 hours, proportionate amounts of the solvents are used.

Yield: 115 mg (30%)

^{1}H-NMR (400 MHz, CD_3OD): δ = 1,32 (t, 3 H), 1,55-2,24 (m, 8 H), 3,02 (q, 2 H), 3,71 (quint, 1 H), 7,79 (t, 1 H), 7,86 (t, 1 H), 8,02 (d, 1 H), 8,07 (d, 1 H), 8,66 (d, 1 H) , 9,15 (d, 1 H) ppm.

Example 21

cis-7-(4-tert-Butylcyclohexyl)-5-ethyl-2-(1-isoquinolinyl)imidazo[5,1-f][1,2,4]-triazin-4(3H)-one



In analogy to the procedure for Example 1, 318 mg (0,71 mmol) crude cis-4-tert-butyl-N-{1-[3-(1-isoquinolinyl)-5-oxo-4,5-dihydro-1,2,4-triazin-6-yl]propyl}cyclohexanecarboxamide, 164 mg (1,07 mmol) phosphoric trichloride are stirred at reflux for 3 hours, proportionate amounts of the solvents are used.

Yield: 111 mg (36%)

^{1}H-NMR (400 MHz, CD_3OD): δ = 0,85 (s, 9 H), 1,01-2,48 (m, 12 H, t at 1,33), 3,04 (q, 2 H), 3,65 (m, 1 H), 7,78 (t, 1 H), 7,85 (t, 1 H), 8,01 (d, 1 H), 8,06 (d, 1 H), 8,64 (d, 1 H), 9,21 (d, 1 H) ppm.

Example 22

2-(3-Bromo-2-thienyl)-7-cyclopentyl-5-ethylimidazo[5,1-f][1,2,4]triazin-4(3H)-one



In analogy to the procedure for Example 1, 400 mg (0,97 mmol) crude N-{1-[3-(3-bromo-2-thienyl)-5-oxo-4,5-dihydro-1,2,4-triazin-6-yl]propyl}cyclopentanecarboxamide, 298 mg (1,95 mmol) phosphoric trichloride are stirred at reflux for 3 hours, proportionate amounts of the solvents are used.

Yield: 340 mg (89%)

^{1}H-NMR (400 MHz, $CDCl_3$): δ = 1,32 (t, 3 H), 1,66-2,19 (m, 8 H), 3,01 (q, 2 H), 3,57 (quin., 1 H), 7,11 (d, 1 H), 7,49 (d, 1 H) ppm.

Example 23

cis-2-(3-Bromo-2-thienyl)-7-(4-tert-butylcyclohexyl)-5-ethylimidazo[5,1-f][1,2,4]-triazin-4(3H)-one



In analogy to the procedure for Example 1, 611 mg (1,27 mmol) crude cis-N-{1-[3-(3-bromo-2-thienyl)-5-oxo-4,5-dihydro-1,2,4-triazin-6-yl]propyl}-4-tert-butylcyclohexanecarboxamide, 389 mg (2,54 mmol) phosphoric trichloride are stirred at reflux for 3 hours, proportionate amounts of the solvents are used.

Yield: 275 mg (47%)

^{1}H-NMR (400 MHz, CD_3OD): δ = 0,85 (s, 9 H), 1,07-2,42 (m, 12 H, t at 1,29), 2,99 (q, 2 H), 3,50 (m, 1 H), 7,18 (d, 1 H), 7,73 (d, 1 H) ppm.

Example 24

trans-2-(3-Bromo-2-thienyl)-7-(4-tert-butylcyclohexyl)-5-ethylimidazo[5,1-f][1,2,4]-triazin-4(3H)-one



In analogy to the procedure for Example 1, 306 mg (0,64 mmol) crude trans-N-{1-[3-(3-bromo-2-thienyl)-5-oxo-4,5-dihydro-1,2,4-triazin-6-yl]propyl}-4-tert-butylcyclohexanecarboxamide, 292 mg (1,91 mmol) phosphoric trichloride are stirred at reflux for 3 hours, proportionate amounts of the solvents are used.

Yield: 194 mg (66%)

^{1}H-NMR (400 MHz, CD_3OD): δ = 0,90 (s, 9 H), 0,99-1,41 (m, 6 H, t at 1,29), 1,69-2,10 (m, 6 H), 2,97 (q, 2 H), 3,17 (m, 1 H), 7,21 (d, 1 H), 7,76 (d, 1 H) ppm.

Example 25

cis/trans-2-(5-Chloro-2-thienyl)-5-ethyl-7-(4-methylcyclohexyl)imidazo[5,1-f]-[1,2,4]triazin-4(3H)-one



In analogy to the procedure for Example 1, 731 mg (1,85 mmol) crude N-{1-[3-(5-chloro-2-thienyl)-5-oxo-4,5-dihydro-1,2,4-triazin-6-yl]propyl}-4-methylcyclohexanecarboxamide, 851 mg (5,55 mmol) phosphoric trichloride are stirred at reflux for 3 hours, proportionate amounts of the solvents are used.

Yield: 314 mg (45%)

^{1}H-NMR (300 MHz, CD_3OD): δ = 0,87-0,92 (m, 3 H), 1,05-2,20 (m, 12 H, t at 1,26 and 1,27), 2,90-3,00 (m, 2 H), 3,34-3,38 (m, 1 H), 7,08 (d, 1 H), 7,69 (d, 1 H) ppm.

Example 26

7-Cyclobutyl-5-ethyl-2-(2-pyrazinyl)imidazo[5,1-f][1,2,4]triazin-4(3H)-one



200 mg (0.86 mmol, 1 equiv.) of Example 60A are suspended in 10 ml dichloroethane, and 130 mg (1.29 mmol) triethylamine and 102 mg (0.86 mmol) cyclobutanecarbonyl chloride are added. The mixture is stirred at room temperature for one hour, then 198 mg (1.29 mmol) phosphoroxychloride are added. The mixture is stirred at reflux for 3 hours. After cooling down to room temperature, ethyl acetate and saturated $NaHCO_3$ (aq) are added. The organic phase is washed with saturated $NaHCO_3$ (aq),

water and brine, dried over sodium sulfate and evaporated to dryness *in vacuo*. The product is purified by chromatography (flash or column chromatography or preparative HPLC).

Yield: 35 mg (14%)

LC/MS (A): MS (ES+): 297 ($M+H^+$), retention time 2.04 min.

Example 27

7-Cyclopentyl-5-ethyl-2-(2-pyrazinyl)imidazo[5,1-f][1,2,4]triazin-4(3H)-one



In analogy to the procedure for Example 26, 200 mg (0,86 mmol) of Example 60A, 114 mg (0.86 mmol) cyclopentanecarbonyl chloride and proportionate amounts of the other reagents are used.

Yield: 88 mg (33%)

^{1}H-NMR (DMSO-d_6, 200 MHz): δ = 1.2 (t, 3H), 1.5-2.1 (m, 8H), 2.9 (q, 2H), 3.6 (m, 1H), 8.8 (m, 1H), 8.9 (m, 1H), 9.4 (m, 1H), 11.6 (br.s, 1H) ppm.

Example 28 and Example 29

7-(4-tert-Butylcyclohexyl)-5-ethyl-2-(2-pyrazinyl)imidazo[5,1-f][1,2,4]triazin-4(3H)-one



In analogy to the procedure for Example 26, 500 mg (2.15 mmol) of Example 60A, 436 mg (2.15 mmol) 4-tert-butylcyclohexanecarbonyl chloride and proportionate amounts of the other reagents are used.

Yield: 177 mg (23%) cis-isomer

28 mg (3%) trans-isomer

cis-isomer (Example 28):

^{1}H-NMR (DMSO-d_6, 200 MHz): δ = 0.9 (s, 9H), 1.1 (m, 1H), 1.2 (t, 3H), 1.5-1.8 (m, 6H), 2.2 (m, 2H), 2.9 (q, 2H), 3.6 (m, 1H), 8.8 (m, 1H), 8.9 (m, 1H), 9.3 (m, 1H), 11.7 (br. s, 1H) ppm.

trans-isomer (Example 29):

^{1}H-NMR (DMSO-d_6, 200 MHz): δ = 0.9 (s, 9H), 1.2 (t, 3H), 1.2 (m, 3H), 1.6 (m, 2H), 1.8 (m, 2H), 2.0 (m, 2H), 2.9 (q, 2H), 3.2 (m, 1H), 8.8 (m, 1H), 8.9 (m, 1H), 9.4 (m, 1H), 11.6 (br. s, 1H) ppm.

Example 30

7-Cyclopentyl-5-ethyl-2-(2-methyl-1,3-thiazol-4-yl)imidazo[5,1-f][1,2,4]triazin-4(3H)-one



In analogy to the procedure for Example 26, 200 mg (0.60 mmol) of Example 61A, 79 mg (0.60 mmol) cyclopentanecarbonyl chloride and proportionate amounts of the other reagents are used.

Yield: 117 mg (60%)

^{1}H-NMR (DMSO-d_6, 200 MHz): δ = 1.2 (t, 3H), 1.5-1.9 (m, 6H), 2.2 (m, 2H), 2.7 (s, 3H), 2.9 (q, 2H), 3.6 (m, 1H), 8.4 (s, 1H), 11.4 (br. s, 1H) ppm.

Example 31

cis-7-(4-tert-Butylcyclohexyl)-5-ethyl-2-(2-methyl-1,3-thiazol-4-yl)imidazo[5,1-f]-[1,2,4]triazin-4(3H)-one



In analogy to the procedure for Example 26, 250 mg (0.99 mmol) of Example 61A, 202 mg (0.99 mmol) 4-tert-butylcyclohexanecarbonyl chloride and proportionate amounts of the other reagents are used.

Yield: 98 mg (25%) cis-isomer

^{1}H-NMR (DMSO-d_6, 200 MHz): δ = 0.8 (s, 9H), 1.1 (m, 1H), 1.2 (t, 3H), 1.5-1.7 (m, 6H), 2.2 (m, 2H), 2.7 (s, 3H), 2.9 (q, 2H), 3.5 (m, 1H), 8.3 (s, 1H), 11.4 (br. s, 1H) ppm.

Example 32

cis-7-(4-tert-Butylcyclohexyl)-5-ethyl-2-(1,3-thiazol-2-yl)imidazo[5,1-f][1,2,4]-triazin-4(3H)-one



In analogy to the procedure for Example 26, 250 mg (1.05 mmol) of Example 62A, 214 mg (1.05 mmol) 4-tert-butylcyclohexanecarbonyl chloride and proportionate amounts of the other reagents are used.

Yield: 86 mg (21%) cis-isomer

^{1}H-NMR (DMSO-d_6, 200 MHz): δ = 0.8 (s, 9H), 1.1 (m, 1H), 1.2 (t, 3H), 1.5-1.7 (m, 6H), 2.2 (m, 2H), 2.9 (q, 2H), 3.5 (m, 1H), 8.1 (m, 2H), 11.9 (br. s, 1H) ppm.

Example 33

7-Cyclopentyl-5-ethyl-2-(1,3-thiazol-2-yl)imidazo[5,1-f][1,2,4]triazin-4(3H)-one



In analogy to the procedure for Example 26, 150 mg (0.63 mmol) of Example 62A, 84 mg (0.63 mmol) cyclopentanecarbonyl chloride and proportionate amounts of the other reagents are used.

Yield: 73 mg (37%)

^{1}H-NMR (DMSO-d_6, 200 MHz): δ = 1.2 (t, 3H), 1.5-1.9 (m, 6H), 2.1 (m, 2H), 2.9 (q, 2H), 3.5 (m, 1H), 8.1 (m, 2H), 11.9 (br. s, 1H) ppm.

Example 34

7-Cyclopentyl-2-(3,5-difluoro-2-pyridinyl)-5-ethylimidazo[5,1-f][1,2,4]triazin-4(3H)-one



In analogy to the procedure for Example 26, 300 mg (1.12 mmol) of Example 63A, 223 mg (1.68 mmol) cyclopentanecarbonyl chloride and proportionate amounts of the other reagents are used.

Yield: 25 mg (6%)

LC/MS (A): MS (ES+): 346 ($M+H^+$), retention time 2.52 min.

Example 35 and Example 36

7-(4-tert-Butylcyclohexyl)-2-(3,5-difluoro-2-pyridinyl)-5-ethylimidazo[5,1-f][1,2,4]-triazin-4(3H)-one



In analogy to the procedure for Example 26, 500 mg (1.87 mmol) of Example 63A, 569 mg (2.81 mmol) 4-tert-butylcyclohexanecarbonyl chloride and proportionate amounts of the other reagents are used.

Yield: 4 mg (1%) cis-isomer

17.4 mg (3%) trans-isomer

cis-isomer (Example 35):

LC/MS (A): MS (ES+): 416 ($M+H^+$), retention time 3.20 min.

trans-isomer (Example 36):

^{1}H-NMR (DMSO-d_6, 300 MHz): δ = 0.9 (s, 9H), 1.1 (m, 3H), 1.2 (t, 3H), 1.6 (m, 2H), 1.8 (m, 2H), 2.0 (m, 2H), 2.9 (q, 2H), 3.0 (m, 1H), 8.2 (m, 1H), 8.7 (m, 1H), 11.6 (br. s, 1H) ppm.

Example 37

cis-7-(4-tert-Butylcyclohexyl)-2-(1,5-dimethyl-1H-pyrrol-2-yl)-5-ethylimidazo[5,1-f][1,2,4]triazin-4(3H)-one



In analogy to the procedure for Example 26, 250 mg (1.01 mmol) of Example 64A, 205 mg (1.01 mmol) 4-tert-butylcyclohexanecarbonyl chloride and proportionate amounts of the other reagents are used.

Yield: 65 mg (21%) cis-isomer

^{1}H-NMR (DMSO-d_6, 400 MHz): δ = 0.8 (s, 9H), 1.1 (m, 1H), 1.2 (t, 3H), 1.5-1.7 (m, 6H), 2.2 (m, 2H), 2.3 (s, 3H), 2.9 (q, 2H), 3.5 (m, 1H), 3.8 (s, 3H), 6.0 (d, 1H), 7.0 (d, 1H), 12.0 (br. s, 1H) ppm.

Example 38

7-Cyclopentyl-2-(1,5-dimethyl-1H-pyrrol-2-yl)-5-ethylimidazo[5,1-f][1,2,4]triazin-4(3H)-one



In analogy to the procedure for Example 26, 150 mg (0.61 mmol) of Example 64A, 80 mg (0.61 mmol) cyclopentanecarbonyl chloride and proportionate amounts of the other reagents are used.

Yield: 65 mg (33%)

^{1}H-NMR (DMSO-d_6, 200 MHz): δ = 1.2 (t, 3H), 1.5-2.0 (m, 8H), 2.2 (s, 3H), 2.9 (q, 2H), 3.5 (m, 1H), 3.8 (s, 3H), 6.0 (d, 1H), 7.0 (d, 1H), 11.3 (br. s, 1H) ppm.

Example 39

2-(3-Bromo-2-pyridinyl)-7-cyclopentyl-5-ethylimidazo[5,1-f][1,2,4]triazin-4(3H)-one



In analogy to the procedure for Example 26, 100 mg (0.32 mmol) of Example 65A, 43 mg (0.32 mmol) cyclopentanecarbonyl chloride and proportionate amounts of the other reagents are used.

Yield: 30 mg (24%)

^{1}H-NMR (DMSO-d_6, 200 MHz): δ = 1.2 (t, 3H), 1.6 (m, 2H), 1.7 (m, 2H), 1.9 (m, 2H), 2.0 (m, 2H), 2.9 (q, 2H), 3.5 (m, 1H), 7.6 (d/d, 1H), 8.3 (d/d, 1H), 8.7 (d/d, 1H), 11.9 (s, 1H) ppm.

Example 40

cis-2-(3-Bromo-2-pyridinyl)-7-(4-tert-butylcyclohexyl)-5-ethylimidazo[5,1-f]-[1,2,4]triazin-4(3H)-one



In analogy to the procedure for Example 26, 110 mg (0.35 mmol) of Example 65A, 72 mg (0.35 mmol) 4-cis-tert-butylcyclohexanecarbonyl chloride and proportionate amounts of the other reagents are used.

Yield: 92 mg (56%)

^{1}H-NMR (DMSO-d_6, 200 MHz): δ = 0.8 (s, 9H), 1.1 (m, 1H), 1.2 (t, 3H), 1.5-1.7 (m, 6H), 2.2 (m, 2H), 2.9 (q, 2H), 3.4 (m, 1H), 7.6 (d/d, 1H), 8.3 (d/d, 1H), 8.7 (d/d, 1H), 12.0 (s, 1H) ppm.

Example 41

cis-7-(4-tert-Butylcyclohexyl)-2-(3-chloro-2-pyridinyl)-5-ethylimidazo[5,1-f][1,2,4]-triazin-4(3H)-one



In analogy to the procedure for Example 26, 150 mg (0.56 mmol) of Example 66A, 114 mg (0.56 mmol) 4-cis-tert-butylcyclohexanecarbonyl chloride and proportionate amounts of the other reagents are used.

Yield: 106 mg (45%)

^{1}H-NMR (DMSO-d_6, 300 MHz): δ = 0.8 (s, 9H), 1.1 (m, 1H), 1.2 (t, 3H), 1.5-1.7 (m, 6H), 2.2 (m, 2H), 2.9 (q, 2H), 3.4 (m, 1H), 7.7 (d/d, 1H), 8.2 (d/d, 1H), 8.7 (d/d, 1H), 11.9 (s, 1H) ppm.

Example 42

2-(3-Chloro-2-pyridinyl)-7-cyclopentyl-5-ethylimidazo[5,1-f][1,2,4]triazin-4(3H)-one



In analogy to the procedure for Example 26, 150 mg (0.56 mmol) of Example 66A, 75 mg (0.56 mmol) cyclopentanecarbonyl chloride and proportionate amounts of the other reagents are used.

Yield: 119 mg (61%)

^{1}H-NMR (DMSO-d_6, 200 MHz): δ = 1.2 (t, 3H), 1.5-2.0 (m, 8H), 2.9 (q, 2H), 3.4 (m, 1H), 7.7 (d/d, 1H), 8.2 (d/d, 1H), 8.7 (d/d, 1H), 11.9 (s, 1H) ppm.

Example 43

7-Cyclopentyl-5-ethyl-2-(1H-pyrrol-2-yl)imidazo[5,1-f][1,2,4]triazin-4(3H)-one



In analogy to the procedure for Example 26, 150 mg (0.68 mmol) of Example 67A, 91 mg (0.68 mmol) cyclopentanecarbonyl chloride and proportionate amounts of the other reagents are used.

Yield: 100 mg (49%)

^{1}H-NMR (DMSO-d_6, 200 MHz): δ = 1.2 (t, 3H), 1.7 (m, 2H), 1.8 (m, 4H), 2.1 (m, 2H), 2.9 (q, 2H), 3.6 (m, 1H), 6.2 (m, 1H), 7.0 (m, 1H), 7.2 (m, 1H), 11.4 (s, 1H), 11.5 (br. s, 1H) ppm.

Example 44

7-Cyclopentyl-5-ethyl-2-(3-furyl)imidazo[5,1-f][1,2,4]triazin-4(3H)-one



In analogy to the procedure for Example 26, 250 mg (1.14 mmol) of Example 68A, 150 mg (1.14 mmol) cyclopentanecarbonyl chloride and proportionate amounts of the other reagents are used.

Yield: 48 mg (14%)

^{1}H-NMR (DMSO-d_6, 200 MHz): δ = 1.2 (t, 3H), 1.7 (m, 2H), 1.8 (m, 4H), 2.1 (m, 2H), 2.9 (q, 2H), 3.6 (m, 1H), 7.0 (m, 1H), 7.9 (m, 1H), 8.5 (m, 1H), 11.7 (s, 1H) ppm.

Example 45

cis-7-(4-tert-Butylcyclohexyl)-5-ethyl-2-(3-furyl)imidazo[5,1-f][1,2,4]triazin-4(3H)-one



In analogy to the procedure for Example 26, 500 mg (2.27 mmol) of Example 68A, 460 mg (2.27 mmol) 4-cis-tert-butylcyclohexanecarbonyl chloride and proportionate amounts of the other reagents are used.

Yield: 101 mg (12%)

^{1}H-NMR (DMSO-d_6, 300 MHz): δ = 0.8 (s, 9H), 1.1 (m, 1H), 1.2 (t, 3H), 1.6 (m, 2H), 1.8 (m, 4H), 2.2 (m, 2H), 2.9 (q, 2H), 3.6 (m, 1H), 7.0 (m, 1H), 7.9 (m, 1H), 8.5 (m, 1H), 11.7 (br. s, 1H), 11.9 (s, 1H) ppm.

Example 46

cis-7-(4-tert-Butylcyclohexyl)-5-ethyl-2-(1-methyl-1H-pyrrol-2-yl)imidazo[5,1-f]-[1,2,4]triazin-4(3H)-one



In analogy to the procedure for Example 26, 1000 mg (4.29 mmol) of Example 69A, 434 mg (2.14 mmol) 4-cis-tert-butylcyclohexanecarbonyl chloride and proportionate amounts of the other reagents are used.

Yield: 24 mg (2%)

^{1}H-NMR (DMSO-d_6, 300 MHz): δ = 0.8 (s, 9H), 1.1 (m, 1H), 1.2 (t, 3H), 1.6 (m, 6H), 2.2 (m, 2H), 2.9 (q, 2H), 3.5 (m, 1H), 3.9 (s, 3H), 6.1 (m, 1H), 7.1 (m, 2H), 11.4 (s, 1H) ppm.

Example 47

7-Cyclopentyl-5-ethyl-2-(1-methyl-1H-pyrrol-2-yl)imidazo[5,1-f][1,2,4]triazin-4(3H)-one



In analogy to the procedure for Example 26, 500 mg (2.14 mmol) of Example 69A, 142 mg (1.07 mmol) cyclopentanecarbonyl chloride and proportionate amounts of the other reagents are used.

Yield: 36 mg (5%)

^{1}H-NMR (DMSO-d_6, 200 MHz): δ = 1.2 (t, 3H), 1.6 (m, 2H), 1.7 (m, 2H), 1.9 (m, 2H), 2.0 (m, 2H), 2.9 (q, 2H), 3.5 (m, 1H), 3.9 (s, 3H), 6.1 (m, 1H), 7.1 (m, 2H), 11.3 (s, 1H) ppm.

Example 48

5-Ethyl-2-(2-thienyl)-7-[3-(trifluoromethyl)cyclohexyl]imidazo[5,1-f][1,2,4]triazin-4(3H)-one



In analogy to the procedure for Example 1, 160 mg (0,39 mmol) of Example 75A, 165 mg (1,07 mmol) phosphoric trichloride are stirred at reflux for 3 hours, proportionate amounts of the solvents are used.

Yield: 11.9 mg (8%)

^{1}H-NMR (200 MHz, DMSO): δ = 1.20 (t, 3H); 1.50-2.20 (m, 8H); 2.60 (m, 1H); 2.90 (quart., 2H); 3.30 (m, 1H); 7.20 (m, 1H); 7.80 (m, 1H); 8.10 (m, 1H); 12.00 (s, 1H).

Beispiel 49

5-Ethyl-7-(4-methylcyclohexyl)-2-(2-thienyl)imidazo[5,1-f][1,2,4]triazin-4(3H)-one



In analogy to the procedure for Example 1, 150 mg (0,42 mmol) of Example 76A, 165 mg (1,07 mmol) phosphoric trichloride are stirred at reflux for 3 hours, proportionate amounts of the solvents are used.

Yield: 21 mg (15%) of an isomeric mixture

^{1}H-NMR (200 MHz, DMSO): δ = 0.90-1.00 (2d, 3H); 1.20 (2t, 3H); 1.50-2.20 (m, 9H); 2.90 (2 quart., 2H); 3.20 (m, 1H); 7.20 (m, 1H); 7.80 (m, 1H); 8.10 (m, 1H); 12.00 (s, 1H).

Example 50

7-(Cyclohexylmethyl)-5-ethyl-2-(2-thienyl)imidazo[5,1-f][1,2,4]triazin-4(3H)-one



In analogy to the procedure for Example 1, 150 mg (0,42 mmol) of Example 77A, 165 mg (1,07 mmol) phosphoric trichloride are stirred at reflux for 3 hours, proportionate amounts of the solvents are used.

Yield: 100 mg (70%)

^{1}H-NMR (200 MHz, DMSO): δ = 0.90-1.30 (m, 9H); 1.60 (m, 4H), 1.85 (m, 1H); 2.90 (m, 4H); 7.20 (m, 1H); 7.80 (m, 1H); 8.10 (m, 1H); 12.00 (s, 1H).

Example 51

7-(1,4-Dimethylcyclohexyl)-5-ethyl-2-(2-thienyl)imidazo[5,1-f][1,2,4]triazin-4(3H)-one



In analogy to the procedure for Example 1, 150 mg (0,40 mmol) of Example 78A, 165 mg (1,07 mmol) phosphoric trichloride are stirred at reflux for 3 hours, proportionate amounts of the solvents are used.

Yield: 90 mg (63%)

^{1}H-NMR (200 MHz, DMSO): δ = 0.70-2.10 (m, 18H); 2.91 (quart., 2H); 7.20 (m, 1H); 7.80 (m, 1H); 8.10 (m, 1H); 12.20 (s, 1H).

Example 52

7-(1-Adamantyl)-5-ethyl-2-(2-thienyl)imidazo[5,1-f][1,2,4]triazin-4(3H)-one



In analogy to the procedure for Example 1, 169 mg (0,42 mmol) of Example 79A, 329 mg (2,15 mmol) phosphoric trichloride are stirred at reflux for 3 hours, proportionate amounts of the solvents are used.

Yield: 20.5 mg (13%)

^{1}H-NMR (300 MHz, DMSO): δ = 1.20 (t, 3H); 1.80 (m, 6H); 2.10 (m, 3H); 2.25 (m, 6H); 2.80 (quart., 2H); 7.20 (m, 1H); 7.80 (m, 1H); 8.10 (m, 1H); 12.00 (s, 1H).

Example 53 and Example 54

7-(4-tert-Butylcyclohexyl)-5-ethyl-2-(3-pyridinyl)imidazo[5,1-f][1,2,4]triazin-4(3H)-one



In analogy to the procedure for Example 1, 200 mg (0,50 mmol) of Example 80A, 165 mg (1,07 mmol) phosphoric trichloride are stirred at reflux for 3 hours, proportionate amounts of the solvents are used.

Yield: 7 mg (4%) cis-isomer

9 mg (5%) trans-isomer

cis-isomer (Example 53):

^{1}H-NMR ($CDCl_3$, 200 MHz): δ = 0.8 (s, 9H), 1.1 (m, 1H), 1.4 (t, 3H), 1.5-1.7 (m, 6H), 2.4 (m, 2H), 3.0 (q, 2H), 3.6 (m, 1H), 7.5 (m, 1H), 8.3 (m, 1H), 8.8 (m, 1H), 9.2 (s, 1H), 9.9 (s, 1H) ppm.

trans-isomer (Example 54):

^{1}H-NMR ($CDCl_3$, 200 MHz): δ = 0.8 (s, 9H), 1.2 (m, 3H), 1.3 (t, 3H), 1.8 (m, 4H), 2.1 (m, 2H), 3.0 (q, 2H), 3.2 (m, 1H), 7.5 (m, 1H), 8.3 (m, 1H), 8.8 (m, 1H), 9.3 (s, 1H), 10.2 (s, 1H) ppm.

Example 55

7-(4-cis-tert-Butylcyclohexyl)-5-ethyl-2-(2-pyridinyl)imidazo[5,1-f][1,2,4]triazin-4(3H)-one



In analogy to the procedure for Example 1, 200 mg (0,50 mmol) of Example 81A, 165 mg (1,07 mmol) phosphoric trichloride are stirred at reflux for 3 hours, proportionate amounts of the solvents are used.

Yield: 44 mg (23%)

^{1}H-NMR (d_6-DMSO, 200 MHz): δ = 0.8 (s, 9H), 1.1 (m, 1H), 1.2 (t, 3H), 1.5-1.7 (m, 6H), 2.4 (m, 2H), 2.9 (q, 2H), 3.6 (m, 1H), 7.6 (m, 1H), 8.1 (m, 1H), 8.2 (m, 1H), 8.7 (m, 1H), 11.3 (s, 1H) ppm.

Example 56

7-(4-cis-tert-Butylcyclohexyl)-5-ethyl-2-(4-pyridinyl)imidazo[5,1-f][1,2,4]triazin-4(3H)-one



In analogy to the procedure for Example 1, 200 mg (0,42 mmol) of Example 82A, 165 mg (1,07 mmol) phosphoric trichloride are stirred at reflux for 3 hours, proportionate amounts of the solvents are used.

Yield: 9.6 mg (5%)

^{1}H-NMR (d_6-DMSO, 200 MHz): δ = 0.8 (s, 9H), 1.1 (m, 1H), 1.2 (t, 3H), 1.5-1.7 (m, 6H), 2.2 (m, 2H), 2.9 (q, 2H), 3.6 (m, 1H), 7.9 (m, 2H), 8.8 (m, 2H), 11.9 (s, 1H) ppm.

Example 57

7-(4-cis-tert-Butylcyclohexyl)-2-(2,5-dichloro-1,3-thiazol-4-yl)-5-ethylimidazo[5,1-f][1,2,4]triazin-4(3H)-one



In analogy to the procedure for Example 1, 50 mg (0,11 mmol) of Example 83A, 165 mg (1,07 mmol) phosphoric trichloride are stirred at reflux for 3 hours, proportionate amounts of the solvents are used.

Yield: 11.7 mg (24%)

^{1}H-NMR (d_6-DMSO, 200 MHz): δ = 0.8 (s, 9H), 1.1 (m, 1H), 1.2 (t, 3H), 1.5-1.7 (m, 6H), 2.2 (m, 2H), 2.9 (q, 2H), 3.5 (m, 1H), 11.9 (s, 1H) ppm.

Example 58

7-(4-tert-Butylcyclohexyl)-5-ethyl-2-(2-furyl)imidazo[5,1-f][1,2,4]triazin-4(3H)-one



In analogy to the procedure for Example 1, 250 mg (0,65 mmol) of Example 84A, 250 mg (1,61 mmol) phosphoric trichloride are stirred at reflux for 3 hours, proportionate amounts of the solvents are used.

Yield: 67 mg (28%)

^{1}H-NMR (d_6-DMSO, 200 MHz): δ = 0.8 (s, 9H), 1.1 (m, 1H), 1.2 (t, 3H), 1.5-1.7 (m, 6H), 2.1 (m, 2H), 2.9 (q, 2H), 3.5 (m, 1H), 6.7 (m, 1H), 7.5 (m, 1H), 7.9 (m, 2H), 11.8 (s, 1H) ppm.

We claim

1. Compounds of the general formula (I),



(I)

in which

R^1 denotes 5- to 10-membered heteroaryl, which is optionally substituted by identical or different residues selected from the group consisting of halogen, (C_1-C_4)-alkyl, trifluoromethyl, phenyl, cyano, nitro und trifluoromethoxy,

and

R^2 denotes 3- to 10-membered carbocyclyl or carbon-bonded, 4- to 10-membered heterocyclyl, whereby carbocyclyl and heterocyclyl are optionally substituted by identical or different residues selected from the group consisting of (C_1-C_6)-alkyl, (C_1-C_6)-alkoxy, hydroxy, halogen, trifluoromethyl and oxo,

or

denotes (C_2-C_{10})-alkyl, which is optionally substituted by identical or different residues selected from the group consisting of (C_1-C_6)-alkoxy, hydroxy, halogen, 3- to 10-membered carbocyclyl and oxo,

and their salts, hydrates and/or solvates.

2. Compounds according to claim 1, whereby

R^1 denotes furanyl, thiophenyl, thiazolyl, pyridyl, chinolyl or isochinolyl, which are optionally substituted by identical or different residues selected from the group consisting of halogen, (C_1-C_4)-alkyl, trifluoromethyl, cyano, nitro und trifluoromethoxy.

3. Compounds according to claim 1 or 2, whereby

R^2 denotes (C_4-C_7)-cycloalkyl, which is optionally substituted up to two times by identical or different (C_1-C_5)-alkyl residues, or
denotes (C_3-C_8)-alkyl, which is optionally substituted by a (C_4-C_7)-cycloalkyl.

4. A process for the preparation of the compounds according to claim 1, characterized in that, compounds of the general formula (IV),



(IV)

in which R^1 and R^2 have the meaning indicated in claim 1,
are reacted with a dehydrating agent.

5. Compounds of the general formula (IV) according to claim 4.

6. Compounds according to any one of claims 1 to 3 for therapeutic and/or prophylactic use.

7. Pharmaceutical composition containing at least one compound according to any one of claims 1 to 3 and a pharmacologically acceptable diluent.

8. Use of compounds according to any one of claims 1 to 3 for the preparation of medicaments.

9. Use of compounds according to any one of claims 1 to 3 for the preparation of medicaments for the treatment and/or prophylaxis of inflammatory processes and/or immune diseases.

10. Use of compounds according to any one of claims 1 to 3 for the preparation of medicaments for the treatment and/or prophylaxis of chronic obstructive pulmonary disease and/or asthma.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP 02/05540

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C07D409/04 C07D417/04 C07D401/04 C07D407/04 C07D403/04
C07D487/04 A61K31/53 A61P37/00 A61P29/00 A61P11/00
A61P11/06

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 C07D A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)
EPO-Internal, WPI Data, PAJ, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	WO 01 64677 A (NIEWOEHNER ULRICH ;HANING HELMUT (DE); BAYER AG (DE); BISCHOFF ERW) 7 September 2001 (2001-09-07) page 34 -page 39; examples	1-10
Y	EP 1 092 719 A (PFIZER LTD ;PFIZER (US)) 18 April 2001 (2001-04-18)	1-4,6-10
Y	page 2 -page 4	5
Y	WO 99 67244 A (NIEWOEHNER ULRICH ;HANING HELMUT (DE); BAYER AG (DE); BISCHOFF ERW) 29 December 1999 (1999-12-29) page 2; examples	1-4,6-10
Y	DE 197 50 085 A (BAYER AG) 20 May 1999 (1999-05-20) examples 13A,18A,72-81; table A	1-4,6-10

-/--

[X] Further documents are listed in the continuation of box C.

[X] Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
9 September 2002	25/09/2002

Name and mailing address of the ISA	Authorized officer
European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Fazzi, R

Form PCT/ISA/210 (second sheet) (July 1992)

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP 02/05540

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	EP 0 009 384 A (GLAXO GROUP LTD) 2 April 1980 (1980-04-02) page 1 -page 2; examples	5
Y	US 3 941 785 A (CLARKE ROBERT WILLIAM ET AL) 2 March 1976 (1976-03-02) column 1, line 14 -column 2, line 63; examples	1-4,6-10
Y	DE 28 11 780 A (ALLEN & HANBURYS LTD) 28 September 1978 (1978-09-28)	1-10
Y	page 10 -page 14; examples	5
Y	US 3 840 537 A (GARSIDE S ET AL) 8 October 1974 (1974-10-08) column 1; examples	1-10
Y	CHARLES I ET AL: "BICYCLIC HETEROCYCLES WITH NITROGEN AT THE RING JUNCTION. PART 2.1 APPLICATION OF THE DAKIN-WEST REACTION TO THE SYNTHESIS OF IMIDAZO-U5,1-F-1,2,4-TRIAZIN-4(3H)-ONES" JOURNAL OF THE CHEMICAL SOCIETY, PERKIN TRANSACTIONS 1, CHEMICAL SOCIETY. LETCHWORTH, GB, no. 5, 1 May 1980 (1980-05-01), pages 1139-1146, XP002027191 ISSN: 0300-922X page 1139 -page 1143	1-10
A	US 5 932 578 A (HWANG SAN-BAO ET AL) 3 August 1999 (1999-08-03) table 1	5
A	GB 1 601 132 A (SMITH KLINE FRENCH LAB) 28 October 1981 (1981-10-28) the whole document	5
A	GB 1 601 133 A (SMITH KLINE FRENCH LAB) 28 October 1981 (1981-10-28) the whole document	5

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No
PCT/EP 02/05540

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 0164677 A	07-09-2001	DE 10010067 A1	06-09-2001
		AU 4063701 A	12-09-2001
		WO 0164677 A1	07-09-2001
EP 1092719 A	18-04-2001	BR 0004779 A	29-05-2001
		EP 1092719 A2	18-04-2001
		JP 2001151778 A	05-06-2001
WO 9967244 A	29-12-1999	DE 19827640 A1	23-12-1999
		AU 4608099 A	10-01-2000
		WO 9967244 A1	29-12-1999
		EP 1090003 A1	11-04-2001
		JP 2002518500 T	25-06-2002
DE 19750085 A	20-05-1999	DE 19750085 A1	20-05-1999
		AT 213246 T	15-02-2002
		AU 738675 B2	20-09-2001
		AU 1558799 A	31-05-1999
		BG 104406 A	31-08-2001
		BR 9812785 A	10-10-2000
		CA 2309332 A1	20-05-1999
		CN 1278822 T	03-01-2001
		DE 19881732 C1	31-01-2002
		DE 19881732 D2	24-08-2000
		DE 59803108 D1	21-03-2002
		DK 1049695 T3	13-05-2002
		DK 200000766 A	09-05-2000
		EE 200000291 A	15-06-2001
		WO 9924433 A1	20-05-1999
		EP 1174431 A2	23-01-2002
		EP 1049695 A1	08-11-2000
		FI 20001086 A	09-05-2000
		GB 2346877 A ,B	23-08-2000
		HR 20000292 A1	30-04-2001
		HU 0100394 A2	28-09-2001
		JP 2001522851 T	20-11-2001
		LU 90561 A1	01-12-2000
		NO 20002444 A	11-05-2000
		NO 20021714 A	11-05-2000
		NZ 504436 A	31-08-2001
		PL 340400 A1	29-01-2001
		SE 0001745 A	11-05-2000
		SI 1049695 T1	30-06-2002
		SK 7092000 A3	12-03-2001
		TR 200001338 T2	21-08-2000
		US 6362178 B1	26-03-2002
		ZA 9810297 A	20-05-1999
EP 0009384 A	02-04-1980	AU 5090979 A	21-02-1980
		CA 1103670 A1	23-06-1981
		DK 388079 A	19-03-1980
		EP 0009384 A1	02-04-1980
		ES 484219 A1	01-10-1980
		FI 792883 A	19-03-1980
		GB 2031423 A ,B	23-04-1980
		IE 48829 B1	29-05-1985
		JP 55040700 A	22-03-1980
		US 4308384 A	29-12-1981

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No
PCT/EP 02/05540

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
EP 0009384 A		ZA	7904910 A	27-08-1980
US 3941785 A	02-03-1976	GB	1457873 A	08-12-1976
		AT	336029 B	12-04-1977
		AT	2374 A	15-08-1976
		AU	474078 B	15-07-1976
		AU	6377473 A	19-06-1975
		BE	809369 A1	03-07-1974
		CA	1005057 A1	08-02-1977
		CH	618170 A5	15-07-1980
		DE	2364076 A1	18-07-1974
		ES	422001 A1	01-08-1976
		FI	57260 B	31-03-1980
		FI	793137 A	10-10-1979
		FR	2213058 A1	02-08-1974
		IE	38681 B1	10-05-1978
		IL	43872 A	31-01-1979
		JP	49095994 A	11-09-1974
		LU	69099 A1	02-04-1974
		NL	7400095 A	08-07-1974
		NO	140301 B	30-04-1979
		SE	408179 B	21-05-1979
		ZA	7309534 A	27-11-1974
DE 2811780 A	28-09-1978	GB	1584461 A	11-02-1981
		AT	363952 B	10-09-1981
		AT	196378 A	15-02-1981
		AU	516179 B2	21-05-1981
		AU	3431478 A	27-09-1979
		BE	865125 A1	21-09-1978
		DE	2811780 A1	28-09-1978
		DK	109578 A	26-09-1978
		ES	468119 A1	01-09-1979
		FI	780828 A	26-09-1978
		FR	2384773 A1	20-10-1978
		IE	46653 B1	10-08-1983
		IT	1105177 B	28-10-1985
		JP	53119891 A	19-10-1978
		NL	7803195 A	27-09-1978
		NZ	186699 A	19-12-1980
		SE	7803195 A	26-09-1978
		US	4278673 A	14-07-1981
		ZA	7801458 A	25-04-1979
US 3840537 A	08-10-1974	GB	1400999 A	16-07-1975
		AT	321923 B	25-04-1975
		AU	472127 B	20-05-1976
		AU	4819172 A	16-05-1974
		BE	791025 A1	07-05-1973
		CA	990292 A1	01-06-1976
		CH	594671 A5	13-01-1978
		DE	2255172 A1	24-05-1973
		DK	138691 B	16-10-1978
		ES	408736 A1	01-03-1976
		FR	2160407 A1	29-06-1973
		IE	37046 B1	27-04-1977
		IL	40686 A	31-12-1975
		JP	1059812 C	25-08-1981

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No
PCT/EP 02/05540

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 3840537 A		JP 48057993 A	14-08-1973
		JP 56003873 B	27-01-1981
		NL 7215646 A	22-05-1973
		PH 9669 A	10-02-1976
		SE 402915 B	24-07-1978
		ZA 7207532 A	25-07-1973
US 5932578 A	03-08-1999	AU 727846 B2	04-01-2001
		AU 2425497 A	17-10-1997
		CA 2249999 A1	02-10-1997
		EP 0889884 A1	13-01-1999
		JP 2002515870 T	28-05-2002
		WO 9735849 A1	02-10-1997
		US 6060470 A	09-05-2000
		US 6380192 B1	30-04-2002
GB 1601132 A	28-10-1981	AR 223643 A1	15-09-1981
		AT 358593 B	25-09-1980
		AT 190478 A	15-02-1980
		AU 514811 B2	26-02-1981
		AU 3379278 A	06-09-1979
		BE 864992 A1	18-09-1978
		BG 33157 A3	15-12-1982
		CA 1124717 A1	01-06-1982
		CH 638804 A5	14-10-1983
		CS 208746 B2	15-09-1981
		DD 134522 A5	07-03-1979
		DE 2811477 A1	21-09-1978
		DK 121978 A	20-09-1978
		EG 13240 A	31-12-1980
		ES 467953 A1	01-11-1978
		FI 780629 A	20-09-1978
		FR 2383943 A1	13-10-1978
		GR 66122 A1	16-01-1981
		HU 175669 B	28-09-1980
		IE 46966 B1	16-11-1983
		IE 46967 B1	16-11-1983
		IL 54111 A	31-07-1981
		IN 147613 A1	03-05-1980
		IT 1095458 B	10-08-1985
		JP 53116392 A	11-10-1978
		LU 79266 A1	29-06-1978
		NL 7802959 A	21-09-1978
		NO 780970 A ,B,	20-09-1978
		NZ 186511 A	14-11-1980
		PL 205382 A1	26-03-1979
		PT 67687 A ,B	01-03-1978
		SE 7803113 A	20-09-1978
		SU 733517 A3	05-05-1980
		US 4220767 A	02-09-1980
		US 4185103 A	22-01-1980
		YU 65278 A1	31-08-1982
		ZA 7800988 A	27-06-1979
		ZM 3278 A1	21-12-1978
GB 1601133 A	28-10-1981	NONE	